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ABSTRACT OF THE DISSERTATION
LABORATORY AND EPIDEMIOLOGICAL CHARACTERISTICS OF ZIKA VIRUS
INFECTIONS IN FLORIDA
by
Stephen White
Florida International University, 2020
Miami, Florida
Professor Mary Jo Trepka, Major Professor
Until recently, Zika virus (ZIKV) was an obscure virus that rarely caused
infections and was unknown to most. In 2015 and 2016, ZIKV came into the public
spotlight as Brazil and other countries began to report large increases in infections with
ZIKV and reported potential complications with developing fetuses and neurologic
manifestations. In 2016, the state of Florida identified and responded to an outbreak of
locally acquired ZIKV infections in Miami-Dade County. This dramatic increase in
infections demonstrated both its importance as an emerging infectious disease and the
paucity of knowledge surrounding ZIKV. This study seeks to utilize the data collected
during the ZIKV pandemic to further characterize the virus and examine the efficacy of
current diagnostic algorithms.
First, a systematic review was conducted to pool data from the literature on
existing cases of ZIKV infections. Markov chain Monte Carlo modeling was used to
determine a median incubation time of 6.5 days for infections with ZIKV. Median time to
viral RNA clearance varied significantly by specimen type. Vaginal specimens
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demonstrated the shortest time to viral RNA clearance (9.9 days); whereas blood
specimens exhibited the longest (49.2 days).
Second, specimens from 934 symptomatic, non-congenitally acquired cases of
ZIKV infection were analyzed to identify factors that contribute to the progression of
viral load, as represented by the detection of ZIKV RNA. ZIKV RNA was detected most
often in urine specimens and also was found to have higher viral loads than serum and
whole blood specimens. Viral load was observed to be lower in non-pregnant women
than pregnant women.
Last, an evaluation of the Centers for Disease Control and Prevention’s (CDC)
2017 and 2019 ZIKV testing algorithms was conducted using data from all confirmed
and probable cases identified in Florida between 2016 and 2018 (n = 1,522). ZIKV RNA
was detected most frequently in urine specimens. When testing required plaque reduction
neutralization test (PRNT) to discern between ZIKV and dengue virus, the PRNT assay
was only able to discriminate between viruses about half of the time. Reducing the
specimen collection window in the 2019 CDC algorithm resulted in fewer conclusive
results.
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Chapter 1
Introduction
Background
The Zika virus (ZIKV) is an RNA virus that belongs to the Flaviviridae family,
Flavivirus genus (1). Most Flavivirus species, including ZIKV, are transmitted through
mosquito or tick vectors. Of note, several other clinically important species of viruses,
including yellow fever virus (YFV), dengue virus (DENV), West Nile virus (WNV), and
St. Louis encephalitis virus, share the same genus. The ZIKV was first isolated in 1947 in
Uganda (2) and has since spread globally, causing an international outbreak in 2015 and
2016.
Between its discovery in 1947 and 2007, only 14 cases of ZIKV infection in
humans were reported (3). Several serosurveys that indicated the potential for endemicity
of ZIKV in many African and Asian countries were conducted in the latter half of the 20th
century. However, results of these surveys must be interpreted with caution due to
incomplete data, variation in laboratory methods, and the high rate of cross-reactivity
among the different species of the Flavivirus genus (4).
In 2007, an outbreak of ZIKV was detected on Yap Island in the Federated States
of Micronesia. Forty-nine confirmed and 59 probable ZIKV infections were identified
during the investigation (5). Results of a serosurvey indicated that approximately 73% of
residents of the island had been infected with the virus, potentially indicating the ability
of ZIKV to spread easily. In 2015, ZIKV was identified in Brazil (6). By the end of the
year, an estimated 440,000 to 1,300,000 cases of ZIKV infection were projected to occur
in the country (7). Because of the observed increase in microcephaly and neurological

1

disorders, such as Guillain-Barré syndrome, the World Health Organization (WHO)
declared a Public Health Emergency of International Concern (PHEIC) on February 1,
2016 (8). In 2016, Florida experienced a large increase of travel-associated ZIKV
infections (9). Later that summer, local transmission was detected in Miami-Dade
County, resulting in 285 cases of ZIKV infection (10). By the summer of 2017, the Pan
American Health Organization (PAHO) had reported a total of 794,053 suspected,
confirmed, and imported cases of the disease in the Americas (11). Congenital
abnormalities associated with these infections were confirmed in 3,539 of these cases. By
2019, ZIKV transmission had been reported in almost every country in the Americas.
Although the outbreak has since slowed, the transmission of ZIKV is ongoing and
continues to impact countries. During 2019, 33,896 ZIKV cases were reported to PAHO,
6,640 of which were confirmed cases (12).
The outbreak of ZIKV across the globe has elevated a once obscure disease to the
forefront of medicine and public health. In the last four years (2016 through 2019), 6,707
citations were indexed in PubMed containing “Zika” in the article title or abstract as
compared to only 141 before 2016 (13). Despite the increased opportunity and
availability of data, many questions are left unanswered.
Original estimates of the incubation period of ZIKV infection and viral clearance
are rooted in a single systematic review performed in 2016 shortly following the PHEIC
announcement by the WHO (14). Twenty publications, with case data from only 25
individuals, were included. Notably, this review focused only on blood specimens (whole
blood, serum, and plasma), as the objective of the study was to estimate risk of
transfusion-transmitted infections through blood donation. Since the PHEIC declaration,
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many more case reports, case series, and observational studies have been published.
These reports not only offer an expanded body of work from which to draw conclusions,
but often utilize a wider breadth of clinical specimens to detect the virus, including whole
blood, serum/plasma, urine, saliva, semen, and others. Recent case reports indicate that
the time to clearance within whole blood specimens may significantly differ than
clearance rates in serum or plasma. In a prospective observational study conducted by
Joguet and colleagues, ZIKV RNA was detected in 3 of 15 patients at 120 days postsymptom onset (15). Froeschl and colleagues also report a case exhibiting detection of
ZIKV RNA longer than 100 days (16). In a point-to-point comparison of whole blood
and plasma specimens, 23 whole blood specimens were positive as compared to 9
corresponding plasma specimens (17). Despite prolonged detection observed in some
specimen types, viral culture is not widely performed. This is partly due to the difficulty
of the procedure and also because of the observed low viral load observed in these
specimens (18). These low viral loads may indicate the detection of RNA by rRT-PCR
does not reflect infectious virus.
An update to this systematic review to include the most recent reports and
covering a greater variety of specimen types is needed to refresh the current
understanding of the virus. Understanding the detection profiles of different specimen
types can assist healthcare providers and epidemiologists in better detecting infections.
Further, detection of the virus in different specimen types may indicate the potential for
other methods of transmission, such as via person-to-person contact.
Several studies offer a glimpse into the course of viral load associated with ZIKV.
Most reports and studies rely on very small sample sizes and unstandardized specimen
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sampling (19-24). These reports provide limited evidence for the duration of positivity by
rRT-PCR, but due to unstandardized testing methods, sporadic nature of specimen
collection, and the limited sample sizes, they can only offer broad generalizations of the
viremia and viruria caused by ZIKV. Differences in viral shedding amongst different
groups have been observed. Prolonged viremia has been observed in case reports of
pregnant women (25, 26), indicating a potential relationship between pregnancy status
and ability to clear the virus. Increased viral loads in pregnant cases would provide
further evidence for this potential relationship. Because YFV and DENV are closely
related to ZIKV, those previously vaccinated or infected may exhibit the ability to clear
the virus more rapidly.
Understanding the complete course of viral load is especially important for
developing and refining laboratory methodologies for the detection of ZIKV in clinical
specimens. This knowledge can also aid epidemiologists in interpreting laboratory values
and performing public health interventions. A more complete picture of the course of
viral load can also assist investigators in understanding the viral kinetics of ZIKV when
antiviral interventions are used as well as understanding the potential implications of
viremia on pregnancy outcomes.
Given the nondescript nature of symptoms, laboratory diagnosis is critical for the
identification of ZIKV infections. Several diagnostic methods were used to identify and
confirm ZIKV infection in patients (18, 27). Viral RNA was detected by rRT-PCR assays
and generally considered confirmatory when positive. Urine has been observed to last
longer following infection and at higher levels than serum (24, 28), potentially making
urine an ideal specimen type. Antibody response to ZIKV was detected by virus-specific
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IgM and plaque reduction neutralization test (PRNT) assays. Because the IgM assay for
ZIKV can produce false-positive results due to antigenic similarities with other
flaviviruses, positive or equivocal IgM results were considered presumptive positive until
confirmed by ZIKV- and DENV-specific PRNT (29). The PRNT was generally
considered the “gold standard” for differentiation and confirmation of arbovirus
infections. However, it has been demonstrated that significant immunological crossreactivity between ZIKV and DENV exists (30-33), creating a significant challenge for
diagnostic laboratories. These issues with the cross-reactivity may be exacerbated when
considering populations with an increased proportion of exposure to DENV or pregnant
cases.
Effective use of laboratory assays is critical in the diagnosis of arboviral
infections. The CDC publishes its recommended testing guidance and algorithms (34,
35), revising them periodically as needed. Testing for ZIKV is grouped by clinical
presentation (symptomatic or asymptomatic) and pregnancy status, due to the increased
risk presented to developing fetuses. Significant changes were made between 2017 and
2019, including changing the specimen collection window for rRT-PCR testing and
including DENV testing due to the cross-reactivity between both viruses.

Study Purpose and Significance
This study examines the natural history of viral load in ZIKV and its role in
clinical diagnosis and outbreak detection. This is first accomplished through systematic
review and analysis of published reports of symptomatic ZIKV infections. Viral load is
further examined using epidemiological and laboratory data collected by the Florida
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DOH from 2016 to 2017 during the ZIKV outbreak. Finally, the utility of testing
guidelines recommended by the Centers for Disease Control and Prevention (CDC) in an
outbreak setting are evaluated using the data from the Florida DOH.
The results of this study will help clinical and public health practitioners interpret
the results from current diagnostic assays for ZIKV and potentially guide the
development of future assays and testing guidelines. Additionally, increased knowledge
of the characteristics of such tests will allow practitioners to target and adapt current
screening programs to the appropriate populations. These results will also inform and
guide public health actions in future endeavors to control the virus.

Specific Aims and Hypotheses
Aim 1: Using a systematic review, estimate the incubation period, infectious period
(based on viral isolation results), and time to viral clearance in individuals infected with
ZIKV in whole blood, serum/plasma, urine, saliva, and semen.
Hypothesis 1a: Detectable viral RNA in whole blood decreases over time slowest
compared to the other specimen types.
Hypothesis 1b: The ability to isolate the virus in culture is very small, averaging no
more than two weeks post-symptom onset.

Aim 2: Using Florida DOH laboratory and surveillance data, estimate the progression of
viremia/viruria and viral clearance in individuals infected with ZIKV in whole blood,
serum, and urine.
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Hypothesis 2a: Detectable viremia/viruria in non-pregnant individuals, demonstrated
by the presence of ZIKV RNA, decreases over time slower in whole blood specimens
than in urine or serum specimens.
Hypothesis 2b: Detectable viral RNA in all three specimen types decreases over time
more slowly in pregnant women than in non-pregnant individuals.
Hypothesis 2c: Detectable viral RNA in all three specimen types decreases faster over
time in individuals previously infected with another flavivirus or vaccinated with the
yellow fever vaccine than in those with no previous infection or vaccine history.

Aim 3: Using Florida DOH laboratory and surveillance data, evaluate the use and timing
of molecular and serological testing to detect and differentiate ZIKV infections in an
outbreak setting.
Hypothesis 3a: In specimens collected within two weeks of symptom onset, reversetranscriptase polymerase chain reaction (RT-PCR) will detect a greater number of
cases than IgM.
Hypothesis 3b: Among RT-PCR positive cases, urine will detect the greatest number
of cases as compared to serum and whole blood.
Hypothesis 3c: Positive or equivocal DENV IgM and IgG results are more likely to
be seen in cases born in countries endemic with dengue fever than those born in the
United States.
Hypothesis 3d: Inconclusive plaque reduction neutralization test (PRNT) results are
more likely to be seen in cases born in countries endemic with dengue fever than
those born in the United States.
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Hypothesis 3e: Inconclusive PRNT results are more likely to be seen in pregnant
cases than those non-pregnant cases.
Hypothesis 3f: A diagnostic algorithm including DENV IgM and IgG testing would
decrease the number of specimens required to be referred for PRNT testing.
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Chapter 2
Literature Review
Identification
The ZIKV belongs to the Flaviviridae family and is a member of the Flavivirus
genus. Members of the Flavivirus genus are single-stranded, positive-sense RNA viruses,
characterized by a type I cap at the 5’ end and one open reading frame (ORF) that
encodes for three structural proteins and seven nonstructural proteins (1, 2). The
structural proteins, the capsid, membrane (M protein), and envelope (E protein), are
critical to the formation of the viral particle. These nonstructural proteins are integral in
the replication of the virus within the host cell. Each virion is approximately 50 nm in
diameter and spherical in shape. The surface of the virus is composed of E and M
proteins arranged symmetrically as an icosahedron (3). Several other clinically important
species of viruses, including YFV, DENV, WNV, and St. Louis encephalitis virus, share
the same genus as ZIKV.
The ZIKV was first isolated from a sentinel rhesus monkey in the April of 1947
(4). Researchers placed platforms of rhesus monkeys in the Zika Forest in Uganda, taking
their temperatures daily. When a monkey exhibited a fever, blood specimens were taken
and injected into both mice and other Rhesus monkeys to demonstrate infectivity. The
following year, the virus was again isolated from Aedes africanus mosquitoes from the
same forest. These isolates were characterized serologically by using antiserum to other
viruses, such as YFV, DENV, WNV, and others, to neutralize activity of the virus before
infecting mice. Through these preliminary studies, it was determined that the virus was a
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distinct, previously undiscovered virus, and was named for the forest where it was first
discovered. ZIKV was later isolated from a pool of Ae. aegypti in Malaysia in 1966 (5)
where it was thought to be circulating amongst wild monkeys.

Emergence and Spread as a Human Pathogen
The first human infections with ZIKV reported in literature were from Nigeria in
1952 (6), although these were later thought to be ascribed to the incorrect virus (5, 7). It
is now thought that a laboratory-acquired infection in a researcher residing in Uganda in
1962 is the first reported infection with ZIKV in a human (8). Numerous serosurveys
have been conducted in Africa, Asia, and the Pacific islands in an attempt to determine
the extent of spread and prevalence of the virus (9, 10). These studies, however, tend to
suffer from complications arising from the serological cross-reactivity between ZIKV and
other closely related viruses, and differences in testing methodologies, making their
findings difficult to interpret.
The first documented outbreak of ZIKV infections occurred in 2007 in Yap State
in the Federated States of Micronesia, located in the western Pacific Ocean. Before this
outbreak, only 14 human infections had been previously reported (2). Of the 158 patients
tested, 49 were confirmed to be infected with the virus, and 59 were considered probable
infections (11). A household serosurvey of residents indicated that 73% of island
residents aged 3 years and older had been infected with the virus, demonstrating the
ability of the virus to establish itself in a community. This outbreak also provided
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valuable clinical and epidemiological information on the symptoms and clinical
progression of the disease (11).
In October of 2013, the first cases of ZIKV infections were recorded in the French
Polynesia, located in the southern Pacific Ocean; by the end of the year, almost 6,000
suspect cases had been identified through public health surveillance systems, indicating
up to 19,000 infections could be present (12). Approximately 11% of the country’s
population is estimated to have sought treatment for ZIKV during the outbreak, which
ended in April 2014 (13). Phylogenetic analysis of virus from this outbreak demonstrated
the strain to be closely related to an isolate from the Yap State outbreak as well as an
isolate identified in Cambodia in 2010 (11). A serosurvey conducted 18 months later
indicated that 49% (95% CI 42% to 57%) of study participants exhibited IgG antibodies
to ZIKV (14). By the beginning of 2014 and into 2015, outbreaks of ZIKV infections
began to appear in neighboring islands in the south Pacific Ocean, including New
Caledonia, the Cook Islands, Easter Island, Vanuatu, the Solomon Islands, and others (13,
15-18).
Molecular evidence suggests that ZIKV may have been introduced into Brazil
between May and December of 2013 (19, 20). However, the first reports of cases of mild
illness presenting with rash did not begin appearing until early 2015. Between February
and April 2015, almost 7,000 such cases had been reported (18). In March of 2015, seven
sera from the state of Bahia, Brazil tested positive for ZIKV by reverse-transcriptase PCR
(RT-PCR); phylogenetic analysis indicated that these isolates were most closely related
to an isolate from the French Polynesia in 2013 (21). During the same month, a cluster of
cases in the state of Rio Grande do Norte, Brazil was tested and identified as the first
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report of autochthonous transmission of ZIKV in the country (22). Unfortunately, ZIKV
infections did not become a reportable condition until 2016, making it challenging to
ascertain the true extent of the outbreak in Brazil in 2015. In September, the Brazilian
Ministry of Health (MOH) estimated that the country would experience between 443,502
and 1,301,140 cases of ZIKV infections by the end of 2015 (23). By 2016, the outbreak
in Brazil had expanded to most of the country’s states (24). By the end of 2016, 130,701
confirmed and 84,618 probable cases had been reported to the MOH (25). A survey in the
state of Bahia conducted between 2015 and 2016, indicated a seroprevalence of 63.3%
(95% CI 59.4% to 66.8%) (26).
Cases of ZIKV infection began appearing in neighboring countries towards the
end of 2015 (27). The first cases of ZIKV infections acquired in Colombia were reported
in October of 2015 (28). Suriname, El Salvador, Guatemala, Paraguay, Venezuela and
Mexico reported locally acquired ZIKV infections in November of 2015 (27). On
February 1, 2016, the Director-General of the WHO declared a PHEIC (29). By the end
of 2016, 48 countries in the Americas region had reported autochthonous transmission of
ZIKV (30). The Pan American Health Organization (PAHO) reported 534,553 probable
and 177,614 confirmed cases of ZIKV infection in the Americas in 2016. Multiple
phylogenetic analyses indicate that the introduction of ZIKV in the Americas originated
in Brazil (20, 31). Further, molecular clock analyses are fairly consistent in estimating
that the introductions into a country typically occurred months before public health
surveillance systems identified these infections, indicating sustained transmission was
ongoing during this time.
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Between January 2015 and February 2016, 116 cases of ZIKV infection were
reported in the United States (32), but none of these cases were acquired within its
borders. By the end of July 2016, 383 travel-associated cases had been detected in the
state of Florida (33). On August 1, 2016, in response to the identification of four locally
acquired cases of ZIKV infections, the CDC issued travel guidance through the Health
Alert Network, recommending pregnant women avoid unnecessary travel to the
Wynwood area in Miami-Dade County, Florida (34). On August 16, 2016, the Florida
Department of Health (DOH) announced another area of local transmission in Miami
Beach, and on October 13, 2016, local transmission in the Little River neighborhood. As
with other introductions, genetic analysis of 39 genomes associated with the outbreak in
Miami-Dade County indicated that the virus was introduced at least two months before
the initial cases were detected in July (35). At the conclusion of 2016, 285 locally
acquired and 1,122 travel-associated cases of ZIKV infection had been identified in
Florida. In 2017, the total number of ZIKV infections reported in the United States
dropped more than 10-fold from 5,168 in 2016 to 452; only seven of these cases in 2017
were determined to be acquired locally (36, 37).
Although the magnitude of the ZIKV infection outbreak has decreased since its
peak in 2016, and the PHEIC was announced over less than a year from its declaration,
ZIKV still remains a concern in the Americas. As of July 2019, the WHO reported that at
least 87 countries or territories had evidence of local transmission of ZIKV (38). Between
2017 and 2019, 123,009 total cases (30,019 confirmed) were reported in the Americas to
PAHO with the majority of these cases coming from Brazil (39). By 2019, only three
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countries in the Americas (mainland Chile, Uruguay, and Canada) had not reported ZIKV
transmission (38).

Transmission and Vectors
The primary mode of transmission of ZIKV is via the bite of infected mosquitoes
(40). There are two main transmission cycles associated with ZIKV transmission: sylvatic
and urban. The sylvatic cycle refers to transmission between non-human primates and
zoophilic mosquito species. Once transmission is established within a human population,
transmission is primarily via the urban cycle, between human hosts and anthrophilic
mosquito species. The species thought to be responsible for most vector borne
transmission is the Ae. aegypti mosquito (40). This species has been implicated both
through field collections and experimental transmission studies (9, 40). Other Aedes
species, such as Ae. albopictus and Ae. hensilii, have also demonstrated the ability to
transmit the virus. The current geographical distribution of Ae. aegypti closely resembles
the spread of the ZIKV infections during the 2016-2018 outbreak. Modeling of vector
distribution, indicated that, out of the 188 countries or territories suitable for Ae. aegypti,
85 (45%) had reported autochthonous transmission of ZIKV (41).
There are three other primary mechanisms of transmission for ZIKV: maternalfetal transmission, blood product transfusions, and sexual transmission. Maternal-fetal
transmission occurs when the virus passes from an infected mother to her infant.
Congenital infection can occur if the virus crosses through the placenta and infects the
unborn child (42). In a prospective cohort study of 291 pregnancies in French Guiana
during the ZIKV infection outbreak, infection of the mother resulted in maternal-fetal
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transmission in 26% of cases; no differences were observed between those that resulted
in congenital infections and those that did not (43). The ZIKV has also been detected and
cultured from breast milk (44, 45), representing another possible route of maternal-fetal
transmission.
Probable transfusion-transmitted infections have also been reported in the
literature (46, 47), although it is often difficult to completely rule out vector-borne
transmission in these cases. During the 2013 outbreak in the French Polynesia, nucleic
acid testing of blood donors identified 42 asymptomatic infections in a four-month period
(48). In February 2016, the Food and Drug Administration issued guidance on donor
deferral and testing for areas with and without local transmission in the United States
(49). Between April and June 2016, ZIKV RNA was identified in 68 blood donors in
Puerto Rico using newly implemented screening procedures for the virus (50),
demonstrating the potential for transmission through the blood supply.
The first case of sexual transmission of ZIKV was likely a case report from 2008
(51). In this case, a male researcher that had recently returned to the United States from
Senegal fell ill with ZIKV disease shortly after his return. Five days following the onset
of his symptoms, his wife, having not recently traveled, also developed similar
symptoms. Although it is impossible to rule out isolated vector-borne transmission or
transmission via direct contact, the couple reported having sexual intercourse prior to the
onset of symptoms. Several other reports of putative male-to-female sexual transmission
have been published (52-54), as well as female-to-male (55), and male-to-male (56)
sexual transmission. The ZIKV has been found in both seminal fluids (57-59) and vaginal
secretions (60, 61). Both the WHO and CDC recommend that males practice safe sex for
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at least three months and females practice safe sex for at least two months following
possible exposure to ZIKV; women that are pregnant should practice safe sex with their
partner for the duration of their pregnancy following possible exposure to the virus (62,
63).

Clinical Presentation
The first report of symptoms associated with ZIKV disease was in a volunteer
experimentally infected with the virus (64). The patient experienced a slight headache, a
short period of mild fever, and malaise approximately 82 hours following inoculation. On
the fifth day of illness, the patient’s headache increased in severity, fever rose slightly,
and he experienced nausea and vertigo. The illness resolved on the morning of the 7th day
with no other sequelae. Infection with ZIKV was confirmed by culturing the virus from
the volunteer and observation of an increase in antibodies to the virus. A cohort of 31
patients from the Yap Island outbreak in 2007 provide the first sizeable sample of people
with ZIKV infection symptoms (11). The most common symptom experienced by the
cohort was a maculopapular or papular rash (90% of patients), followed by fever (65%),
arthritis or arthralgia (65%), nonpurulent conjunctivitis (55%), myalgia (48%), headache
(45%), retro-orbital pain (39%), edema (19%), and vomiting (10%). Rash duration was
approximately 6 days (with a range of 2 to 14 days), and arthralgia lasted for
approximately 3.5 days (1 to 14 days). Symptoms were generally mild with no
hospitalizations or deaths. A systematic review of 52 additional articles and reports
conducted in 2016 found that the most frequently reported symptoms were the same as
those described in the Yap Island outbreak (65).
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Another key finding of the Yap Island outbreak was the ratio of symptomatic
illness to those presenting without symptoms. The authors estimated that approximately
919 residents (18%) infected with ZIKV presented with clinical symptoms (11). This
indicates that approximately 80% of ZIKV infections present with no symptoms. A
systematic review conducted in 2018 identified 23 studies describing the prevalence of
asymptomatic infections (66). The authors observed a large amount of variation in the
prevalence of asymptomatic infections, ranging from 29% to 82%, depending on the
study population. The pooled prevalence of asymptomatic infections was 61.8% (95% CI
33.0% to 87.1%), but the authors note that this estimate may not be robust. Other
arboviruses demonstrate varying prevalence of asymptomatic infections. Approximately
75 to 80% of infections with WNV and DENV are thought to be asymptomatic (67,
68);whereas only about 55% of infections with YFV are thought to be asymptomatic
(69). However, because most infections with ZIKV that do present with symptoms are
mild in nature (9, 11), these estimates could be too high.
With the introduction and dramatic transmission of ZIKV in Brazil, a marked
increase in the number of cases of microcephaly, a birth defect where a newborn’s head
circumference is smaller than normal, was also observed (70). Between 2000 and 2014,
the average annual number of reported cases of microcephaly in Brazil was 157.3; in
2015, 574 cases of microcephaly were reported. A similar increase in microcephaly was
observed in Columbia in 2016; 476 cases of microcephaly were reported between
epidemiologic weeks 5 and 45 as compared to 110 cases during the same time period the
year prior (71). Retrospective analysis of cases during the 2013–2015 French Polynesia
outbreak indicated a similar trend (72). This correlation, in part, led the WHO to declare
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the PHEIC in February 2016 (29). A pattern of other birth defects and anomalies emerged
beyond microcephaly. In addition to severe microcephaly, characteristics of congenital
Zika syndrome (CZS) include brain anomalies, ocular anomalies, congenital contractures,
and neurological complications (73). In a study of 1,450 children aged ≥1 year born to
mothers with ZIKV infection in the United States or its territories, 203 (14%) had at least
one ZIKV-related birth defect or neurodevelopmental abnormality (74).
A similar correlation was seen with ZIKV and Guillain-Barré syndrome (GBS), a
disorder where the patient’s immune system damages the nervous system, causing
weakness or paralysis. During the ZIKV disease outbreak in the French Polynesia, the
incidence rate of GBS was approximately 20 times higher than expected (13). A casecontrol study of 42 French Polynesian patients diagnosed with GBS, 41 (98%) were
positive for IgM or IgG against ZIKV compared with only 35 (36%) of the controls (OR
59.7, 95% CI 10.4 to ∞) (75). ZIKV was detected in two patients who were diagnosed
with GBS in Martinique (76). Out of 56 patients diagnosed with GBS in Puerto Rico
during the first seven months of 2016, 34 (37%) had evidence of ZIKV or flavivirus
infection (77). As of October 2016, the WHO reported that 13 countries had observed an
increase in the incidence of GBS cases; an additional six countries had reported GBS in
patients diagnosed with ZIKV infection (78). A systematic review conducted in 2018
indicated that the incidence rate for Latin American and Caribbean nations increased 2.6
times (95% CI 2.3 to 2.9) during the ZIKV disease outbreak (79).
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Laboratory Methods
Three types of diagnostic assays are predominantly used to identify infections
with ZIKV (80, 81). The first group are those tests that detect the virus’ RNA, or nucleic
acid amplification tests (NAATs). Although there are many variations of these tests,
NAATs detect a genetic sequence (or multiple sequences) of viral RNA specific to ZIKV
and amplify the sequence for detection. These assays are both sensitive and specific,
allowing for the identification of very minute quantities of RNA. Because these assays
detect the virus directly, a positive result in a patient typically indicates an acute infection
with the virus (81, 82).The most common type of NAAT is the real-time reversetranscriptase polymerase chain reaction (rRT-PCR) test. Briefly, these assays mimic the
natural process of DNA replication by first producing complementary DNA (cDNA)
from the virus’ RNA, binding ZIKV-specific primers to the cDNA, and replicating using
a thermostable polymerase (83). Detection is facilitated in “real-time” with fluorescently
labeled probes or other detection chemistries. Reactions can also be multiplexed,
meaning multiple targets (e.g., multiple viruses) can be detected simultaneously (84).
Common genetic targets of current ZIKV NAATs include the envelope, membrane, and
several of the nonstructural proteins (81, 85). Even though rRT-PCR assays are able to
detect very small quantities of virus, the viral load associated with ZIKV infections has
been reported to be substantially lower than other flavivirus infections (86, 87) and may
differ between specimen types (88).
Another common assay type for the diagnosis of ZIKV infection is the enzymelinked immunosorbent assay (ELISA). These assays most frequently look for the
presence of IgM or IgG antibodies against the virus produced by the patient. IgM
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antibodies are typically produced in response to the first time the immune system
encounters a new pathogen and are typically present shortly after infection until a few
months. As the quantity of IgM antibodies wanes, the amount of IgG antibodies, which
typically provide long lasting immunity, increases and often lasts for years. Generally,
the presence of IgM antibodies indicates that the infection was recent (within the last few
weeks or months); whereas the presence of IgG indicates a previous infection (82). Of the
five assays currently approved for use in the United States, all of them detect only IgM
(89, 90); ZIKV IgG assays exist but are not widely used. IgM ELISAs work by coating a
test well with anti-IgM antibodies that will capture the patient’s IgM antibodies from
serum. These bound antibodies are then exposed to a known ZIKV antigen. This process
is detected by adding a fluorescently labeled antibody that will bind to the antigen and
produce a color change. The antigen used for these assays vary, but usually consist of a
non-infectious ZIKV-like particle, the ZIKV envelope, or the ZIKV NS1 protein (85).
The presence of IgM antibodies would indicate that the patient has previously been
infected by the virus, although the timing of such infection is often difficult to intuit. A
recent study demonstrated that 76% of patients with symptomatic ZIKV infection
(confirmed by rRT-PCR) had detectable IgM against ZIKV 25 months following the
initial illness (91), limiting the utility of this test as an indicator of recent infection.
Another complication of these assays is the cross-reactivity observed with other
flaviviruses, especially DENV (81, 85, 92, 93). Under current diagnostic guidance from
the CDC, specimens that test positive for ZIKV IgM should be tested further (82).
The plaque reduction neutralization test (PRNT) is considered the “gold standard”
for serological testing of ZIKV (85). This assay determines if patient antibodies are
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effective at neutralizing live virus to keep it from replicating. The assay can be conducted
with ZIKV, DENV, and other flaviviruses. Patient sera is serially diluted and incubated
with a standard amount of virus (81). This mixture is then inoculated onto a monolayer of
cultured cells on a semisolid medium and incubated. Viral plaques are then counted, and
the dilution resulting in a reduction in 90% of the plaques is considered the endpoint of
the assay. This process is both time- and labor-intensive and typically only available in
select public health laboratories. Because of the cross-reactivity observed in the ZIKV
IgM ELISA, PRNT for both ZIKV and DENV is recommended for positive or equivocal
results (82). However, recent experiences with the PRNT assay have indicated that the
assay is also prone to cross-reactivity with DENV (11, 93), causing difficulty in
interpretation in populations previously exposed to DENV and limiting its utility.
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Chapter 3
Persistence of Zika Virus in Clinical Specimens: A Systematic Review
Background
First isolated in 1947 (1), only 14 cases of human ZIKV infection had been
reported between the discovery of the virus and 2007 (2). However, with the recent
global spread of the virus, a dramatic increase in the number of confirmed and
presumptive cases has been reported (3-6). Despite this impressive surge in cases, little is
known about the time course of viremia and viruria. As the literature expands to include
case reports and observational studies, it is important to coalesce these data to have an
accurate and updated understanding of viral persistence in those infected with the virus.
Understanding the natural history of viral persistence is especially important for
healthcare providers and epidemiologists in interpreting laboratory values and performing
public health interventions. This knowledge can also help in developing laboratory
methodologies for the detection of the virus and refining testing algorithms. A more
complete picture of when ZIKV RNA can be detected in various clinical specimens can
also assist researchers in understanding the kinetics of the virus when antiviral
interventions are used as well as interpreting the potential implications of viral load on
pregnancy outcomes. To this end, a systematic search and review of available literature
was performed to identify published articles and other materials describing the
progression of the virus in various body fluids in uncomplicated, symptomatic ZIKV
infections.
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Methods
Protocol. This systematic review was conducted according to the 2009 Preferred
Reporting Items for Systematic Reviews and Meta-Analyses Guidelines (7) and the
registered protocol (CRD42018092049) can be found on PROSPERO (8).
Eligibility. Original case reports of symptomatic ZIKV infection in humans were
included. Cases without symptom onset or those where infection was putatively acquired
in utero were excluded as the timing of viremia could not be reliably determined. Cases
presented along with significant medical comorbidities (such as simultaneous coinfections, chronic health conditions, or compromised immune status) or as part of an
intervention were excluded in an attempt to limit confounding. Case data from the
validation of laboratory methods were also excluded as to not potentially count cases
more than once.
Outcomes. Two primary outcome measures were examined: exposure and viral
clearance intervals. The exposure interval was defined as the first to the last potential date
of exposure, as determined by the authors presenting the case(s). Where possible, the
viral clearance interval was defined as the date of last positive RT-PCR result to the first
negative RT-PCR result. When no negative result was reported, the last positive RT-PCR
result was utilized as the start of the viral clearance interval and left unbounded during
statistical analysis. Intervals were calculated on whole days only.
Search methodology. A literature search of the CINAHL, EMBASE, LILACS,
and Medline electronic databases was conducted independently by two authors (SLW and
MC) on March 22, 2018. The following generic search phrase was used in each database,
modified to include MeSH terms and subject headings where appropriate: Zika OR ZIKV
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AND viremia OR viraemia OR viruria OR kinetic* OR dynamic* OR progress* OR
“time course” OR clearance OR ((viral OR virus) AND (load OR isolation OR culture))
OR PCR. No limitations were included in the search; all records included up to the date
of the search were included. Covidence Systematic Review Software (Veritas Health
Innovation, Melbourne, Australia) was used to import and screen references. Reviews
were completed independently by two of the authors (SLW and MC). Titles and abstracts
were evaluated for preliminary inclusion in the study by both reviewers. If either
reviewer selected a study for inclusion, the full text was evaluated to ensure applicability
to the review.

35

Table 1. Database search phrases
Database

CINAHL
Current Nursing and Allied
Health Literature

EMBASE
Excerpta Medica dataBASE

Search Phrase
(Zika OR ZIKV OR (MH "Zika Virus Infections") OR
(MH "Zika Virus")) AND (viremia OR viraemia OR
viruria OR kinetic* OR dynamic* OR progress* OR
"time course" OR clearance OR ((viral OR virus)
AND (load OR isolation OR culture)) OR PCR OR
(MH "Viremia") OR (MH "Kinetics") OR (MH
"Disease Progression") OR (MH "Viral Load") OR
(MH "Microbial Culture and Sensitivity Tests") OR
(MH "Polymerase Chain Reaction"))
(Zika OR ZIKV OR 'Zika fever'/de OR 'Zika virus'/de)
AND (viremia OR viraemia OR viruria OR kinetic*
OR dynamic* OR progress* OR "time course" OR
clearance OR ((viral OR virus) AND (load OR
isolation OR culture)) OR PCR OR 'viremia'/de OR
'viruria'/de OR 'kinetics'/de OR 'viral clearance'/de OR
'disease exacerbation'/de OR 'virus load'/de OR 'virus
isolation'/de OR 'virus culture'/de OR 'pcr'/de OR
'polymerase chain reaction'/exp)

LILACS
Literatura Latino-Americana
e do Caribe em Ciências de
Saúde

(Zika OR ZIKV) AND (viremia OR viraemia OR
viruria OR kinetic* OR dynamic* OR progress* OR
"time course" OR clearance OR ((viral OR virus)
AND (load OR isolation OR culture)) OR PCR)

MEDLINE
Medical Literature Analysis
and Retrieval System Online

(Zika OR ZIKV OR MESH.EXACT("Zika Virus
Infection") OR MESH.EXACT("Zika Virus")) AND
(viremia OR viraemia OR MESH.EXACT("Viremia")
OR kinetic* OR MESH.EXACT("Kinetics") OR
dynamic* OR progress* OR MESH.EXACT("Disease
Progression") OR "time course" OR ((viral OR virus)
AND (load OR isolation OR culture)) OR
MESH.EXACT("Viral Load") OR
MESH.EXACT("Virus Cultivation") OR PCR OR
MESH.EXACT.EXPLODE("Polymerase Chain
Reaction"))

Data collection. Each record was assigned a reference number and each case
presented within that record was given a unique subject ID number. For each case, the
following information was extracted when presented: gender, age, special population
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characteristics (e.g. pregnancy status, flavivirus vaccinations, neurological involvement),
number of symptoms, putative country of infection, specimen type, first and last day of
potential exposure, first and last day of symptom onset, date of symptom resolution,
specimen type, RT-PCR test results, cell line, timing of specimen collection, incubation
timing, and detection methodology. Specimen types were simplified into the following
categories: blood, cerebrospinal fluid (CSF), saliva, semen, serum, urine, vaginal,
unknown, and other. Testing data were separated by specimen type. In other words, each
line in the complete dataset represents a single patient and a single specimen type. For
example, if one patient had three specimen types collected and tested, there would be
three separate entries for that patient. Data were extracted by a single author (SLW) and
reviewed for accuracy by a second author (MC); discrepancies were resolved by
consensus.
Quality assessment. To evaluate the quality of each record and the risk of bias, the
National Institute of Health’s Study Quality Assessment Tools for case series studies was
adapted. This tool evaluates studies on elements of the study population, description of
the cases, uniformity of results, methods, and presentation (Figure 1).
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Figure 1. Record quality assessment criteria.
Maximum
Score

Criteria
Does the patient(s) represent(s) the whole experience of the investigator
(center)?
1
1 point for a single case report
1 point for poorly described case series
2 points for case series with described selection method
Was the exposure adequately ascertained?
2
1 point for well-described case history
Was the outcome adequately ascertained?

2

1

0 points for poorly described primary outcomes or if outcomes are
unclear
3

1 point if primary outcomes are not systematically described
amongst cases

2

2 points if primary outcomes are thoroughly and systematically
described amongst all cases
Were other alternative causes that may explain the observation ruled
out?
4
0 points if medical history not provided
1 point if medical history is provided or if additional lab testing
provided
Was follow-up long enough for outcomes to occur?
5
0 points if testing is only conducted at one time point per specimen
2 points if serial testing performed
Is the case(s) described with sufficient details to allow other
investigators to replicate the research or allow practitioners to make
inferences related to their own practice?
6
0 points if case details are not provided
1 point if case details are unclear or incomplete
2 points if details are systematically collected and complete for all
cases
Was a more advanced study design, such as a cohort design, utilized?
7
0 points if only a case study or case series
2 points if cohort study conducted
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1

2

2

2

Statistical analysis. Descriptive statistics were calculated using SAS software
version 9.4 (Cary, NC, USA). Incubation period and viral clearance rates were estimated
using methods similar to those described by Lessler and colleagues (9). Briefly, upper
and lower bounds were extracted from case data for the time of exposure, time of
symptom onset, first and last positive RT-PCR results, and first negative RT-PCR result.
Using Markov chain Monte Carlo (MCMC) modeling, these bounds were used to
estimate the incubation period of ZIKV disease (time from exposure to symptom onset)
and the time to viral clearance (from symptom onset). MCMC modeling was conducted
using R statistical language (Vienna, Austria) with the JAGS package, version 4.10.

Results
Search Results
4,803 references (Figure 2) were identified from CINAHL (n = 600), EMBASE (n
= 1,879), LILACS (n = 1,122), and MEDLINE (n = 1,202). Of these, 2,051 were
identified as duplicate references and removed. The titles and abstracts of the remaining
2,750 references were screened for inclusion. 2,324 were excluded, leaving 426 full-text
articles to be evaluated. Of these 426 articles, 289 were excluded, leaving 137 citations
for inclusion into the study. One of these citations was a follow-up report on a previously
included article.
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Figure 2. Record selection flow chart.

CINAHL
n = 600

EMBASE
n = 1,879

4,803
Records Imported

2,750
Records Screened by
Title and Abstract

LILACS
n = 1,122

MEDLINE
n = 1,202

2,051 Duplicate Records
Removed

2,324 Records Excluded
• 1,366 wrong population
• 594 secondary data
• 221 wrong publication type
• 143 wrong outcome

426
Full-text Records
Evaluated

289 Records Excluded:
• 183 wrong outcome
• 53 wrong population
• 33 secondary data

136
Records Included

1 Record Excluded:
• Duplicate case

Record Quality
Of the 137 records included in the study, 136 were reviewed for quality; the
remaining record was an update to another study already included. The possible range of
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scores was from 0 to 12, higher scores indicating a higher quality. The median score was
7 with a range of 0 to 12 (Table 2).

Table 2. Frequency of record quality scores.
Possible
Score
0
1
2
3
4
5
6
7
8
9
10
11
12

No.
Records
2
0
0
1
11
17
21
26
28
15
7
6
2

Patient Results
Data were abstracted from 792 patients from the 136 records. A median of 2
specimen types were reported for each patient (range: 1 to 6), resulting in 1,571 total
entries. Availability of data varied greatly amongst the records. Amongst the patient-level
data, gender was missing from 180 patients (22.7%), and age was available for only
65.2% of patients (Table 3). Complete exposure data was available for only 93 (11.7%)
cases. Data on symptom presentation were available on less than half of all cases.
Notably, the putative source of infection was presented in the majority of cases (77.8%).
Specimen type was available in 99.2% (1,559) of specimen-level data. Unsurprisingly,

41

the availability of testing data varied. The earliest positive result was available in 67.9%
of specimens (1,067), but the last positive result was presented in only 15.7% of records.
A negative result, however, was available in about half of the specimens (53.2%).

Table 3. Availability of patient- and specimen-level data available.
Female
n (%)

Male
n (%)

Unknown
n (%)

Total
n (%)

Total
Age*

285
256 (89.8)

327
260 (79.5)

180
0 (0.0)

792
516 (65.2)

Symptoms*
Source of
infection*
Exposure period*
Symptom
duration*
Exposure period
and symptom
onset*
Specimen type
Earliest positive
result
Last positive result
First negative
result
All three

122 (42.8)

147 (45.0)

50 (27.8)

319 (40.3)

255 (89.5)

283 (86.5)

78 (43.3)

616 (77.8)

48 (16.8)

75 (22.9)

0 (0.0)

123 (15.5)

35 (12.3)

53 (18.6)

0 (0.0)

88 (11.1)

41 (14.4)

52 (14.1)

0 (0.0)

93 (11.7)

526 (99.6)

684 (98.6)

349 (100.0)

1559 (99.2)

357 (67.6)

444 (84.1)

266 (50.4)

1067 (67.9)

75 (14.2)

149 (28.2)

23 (4.4)

247 (15.7)

279 (52.8)

430 (81.4)

126 (23.9)

835 (53.2)

53 (10.0)

114 (16.4)

20 (5.7)

187 (11.9)

PCR assay type

495 (93.8)

638 (91.9)

328 (94.0)

1461 (93.0)

*Age, symptoms, source of infection, exposure period, and symptom duration are derived
from patient-level data (n = 792); all others derived from specimen-level data (n = 1,571).

285 (36.0%) of the patients were female and 327 (41.3%) were male; the gender
of 180 (22.7%) patients was not described (Table 4). Thirty-six (12.3%) of the female
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patients were pregnant. Thirty-five (4.4%) of the cases exhibited neurological
complications, such as GBS or encephalitis.

Table 4. Case characteristics.

Total
Age (years)
Mean
Range
0-4
5-9
10-19
20-29
30-39
40-49
50-59
≥60
Not described
Special
population
Pregnant
Neurological
complications
Number of key
symptoms
Zero
One
Two
Three
Four
Five
Six
Not described

Female
n (%)
285 (36.0)

Male
n (%)
327 (41.3)

Unknown
n (%)
180 (22.7)

Total
n (%)
792

32.8
0 to 80
10 (3.5)
16 (5.6)
31 (10.9)
53 (18.6)
58 (20.4)
42 (14.7)
27 (9.5)
19 (6.7)
29 (10.2)

34.7
1 to 80
5 (1.5)
18 (5.5)
28 (8.6)
41 (12.5)
62 (19.0)
66 (20.2)
22 (6.7)
18 (5.5)
67 (20.5)

0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
180 (100.0)

33.7
0 to 80
15 (1.9)
34 (4.3)
59 (7.5)
94 (11.9)
120 (15.2)
108 (13.6)
49 (6.2)
37 (4.7)
276 (34.9)

36 (12.3)

-

-

36 (4.6)

14 (4.9)

21 (6.4)

0 (0.0)

35 (4.4)

2 (0.7)
18 (6.3)
30 (10.5)
26 (9.1)
34 (11.9)
12 (4.2)
0 (0.0)
163 (57.2)

1 (0.3)
19 (5.8)
41 (12.5)
37 (11.3)
35 (10.7)
12 (3.7)
2 (0.6)
180 (55.0)

2 (1.1)
7 (3.9)
15 (8.3)
16 (8.9)
9 (5.0)
0 (0.0)
1 (0.6)
130 (72.2)

5 (0.6)
44 (5.6)
86 (10.9)
79 (10.0)
78 (9.8)
24 (3.0)
3 (0.4)
473 (59.7)

Serum specimens were collected most often, representing approximately half of
the dataset (46.0%); urine specimens represented 27.1% of the dataset (Table 5). Notably,
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semen specimens represent 14.6% (101) of the specimens tested for male patients;
whereas vaginal specimens only accounted for 5.3% (28) of those collected on female
patients. Interestingly, given the heightened attention on neurological involvement, CSF
specimens only represented 1.7% (27) of the dataset.

Table 5. Specimen types by gender.

Specimen type

Female
n (%)
528

Male
n (%)
694

Unknown
n (%)
349

Total
n (%)
1,571

Blood

31 (5.9)

35 (5.0)

15 (4.3)

81 (5.6)

Cerebrospinal fluid

10 (1.9)

17 (2.5)

0 (0.0%)

27 (1.7)

Saliva

35 (6.6)

56 (8.1)

56 (16.1)

147 (9.4)

Semen

-

101 (14.6)

0 (0.0%)

101 (6.4)

Serum

257 (48.67)

287 (41.4)

179 (51.3)

723 (46.0)

Urine

150 (28.4)

177 (25.5)

99 (28.4)

426 (27.1)

Vaginal

28 (5.3)

-

0 (0.0%)

28 (1.8)

Other

15 (2.84)

11 (1.6)

0 (0.0%)

26 (1.7)

Unknown

2 (0.4)

10 (1.4)

0 (0.0%)

12 (0.8)

The exposure period and date of symptom onset (necessary to estimate the
incubation period) was only abstracted from 93 (11.7%) cases. The median exposure
period was 14 days with a range of 0 to 547 days (Table 6). The median time from the
last exposure to symptom onset was 2 days with a range of -10 to 59 days. Using MCMC
modeling, the median incubation period was determined to be 6.5 days (95% credible
interval [CrI]: 5.5 to 7.7 days) with a dispersion 1.7 days (95% CrI: 1.5 to 2.7 days)
(Figure 3). The median duration of symptoms was 7 days with a range of 1 to 60 days.
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No significant differences were observed between genders. The median time to earliest
positive result post-symptom onset for all specimen types was 4 days with a range of -2
to 98 days. The median time to latest positive and first negative result for all specimen
types was 15.5 (range 2 to 188) and 11.0 (range 0 to 256), respectively. Significant
differences were observed between males and females for the timing of the first positive
result and first negative result, but not the latest positive result.

Proportion of cases with
symptoms (%)

Figure 3. Estimated incubation period for symptomatic Zika virus disease.

100

75

50

25

0
0

5

10

15

20

Days from infection

Solid line indicates estimated proportion of cases developing symptoms at days postinfection. Shaded areas indicate 95% CrI.
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Table 6. Primary outcomes by gender.
Interquartile
Median Range
Range

Variable
n (%)
Exposure
period
Female
48 (39.0)
14.5
Male
75 (60.1)
12.0
Total
123 (100.0)
14.0
Symptom
onset
Female
96 (45.7)
2.0
Male
114 (54.3)
1.0
Total
210 (100.0)
2.0
Symptom
duration
Female
35 (39.8)
8.0
Male
53 (60.2)
7.0
Total
88 (100.0)
7.0
DCPSO*
earliest positive
Female
357 (44.6)
3.0
Male
444 (55.4)
5.0
Total
801 (100.0)
4.0
DCPSO*
latest positive
Female
75 (33.5)
14.0
Male
149 (66.5)
18.0
Total
224 (100.0)
15.5
DCPSO* first negative
Female
279 (39.4)
9.0
Male
430 (60.6)
13.0
Total
709 (100.0)
11.0
*days collected post-symptom onset

p-value
0.467

16.5
19.0
17.0

2 to 547
0 to 365
0 to 547
0.883

4.0
5.0
5.0

-8 to 6
-10 to 59
-10 to 59
0.185

8.0
6.0
6.5

2 to 60
1 to 33
1 to 60
<0.001

3.0
4.0
5.0

-2 to 98
-2 to 91
-2 to 98
0.134

24.0
36.0
34.5

2 to 120
2 to 188
2 to 188
0.006

17.0
25.0
20.0

0 to 198
0 to 256
0 to 256

Differences were also observed when examining the timing of results for different
specimen types (Table 7). For earliest positive results, blood, saliva, serum, urine, and
vaginal specimens all had a similar median time to first detection (3 to 5 days). CSF
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appeared to have a slightly longer time to become positive (median 8 days), although this
was observed within a fairly small sample size. Semen specimens, however, did not
become positive until a median of 15 days. There also appeared to be variation amongst
specimen types for the first negative result. Serum specimens were negative within a
median of 6 days post-symptom onset (range 0 to 256); whereas urine specimens were
negative within a median of 20 days (range 0 to 134) and semen 42 days (range 4 to 201).
Similarly, viral clearance estimates varied significantly by specimen type (Table
8, Figure 4). Blood specimens had the longest mean time to viral clearance, 49.2 days
(95% CrI: 33.9 to 80.8 days). Vaginal specimens had the shortest mean time to viral
clearance (9.9 days, 95% CrI: 6.6 to 17.9 days). The time to viral clearance for urine was
determined to be almost twice as long as that of serum (20.5 versus 10.8 days).
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Table 7. Median times to first and last positive and first negative rRT-PCR results.
Blood
CSF
Saliva
Semen
DCPSO Earliest Positive
n
69
10
108
65
Median 5
8
4
15
IQR
5
3
3
20
Range 0 to 98
6 to 16 -2 to 39 3 to 91
DCPSO Latest Positive
n
39
0
25
37
Median 8
13
50
IQR
83
22
50
Range 1 to 140 3 to 91
11 to 188
DCPSO First Negative
n
61
18
68
82
Median 20
14
13
42
IQR
84
9
15.5
67
Range 1 to 140 4 to 27 0 to 134 4 to 201
CSF: cerebrospinal fluid; IQR: interquartile ratio
* Kruskal-Wallis Test

Serum

Urine

Vaginal

Other

Unknown p-value

432
3
3
-2 to 46

348
4
5
-1 to 91

21
4
5
0 to 37

31
3
2
1 to 8

2
6
8
2 to 10

< 0.001

53
11
24
1 to 120

84
13.5
10.5
2 to 80

5
12
1
11 to 14

12
7
2.5
2 to 18

1
12
0
12

< 0.001

404
6
9
0 to 256

162
20
21
0 to 134

25
15
13
7 to 197

27
5
5
0 to 198

0
-

< 0.001

Table 8. Time in days from symptom onset to viral clearance by specimen type.

n
Median
95% CrI

Blood
169
49.2
33.9 to 80.8

CSF
28
19.5
5.9 to 663.6

Saliva
186
18.9
13.9 to 28.9

Semen
159
47.7
35.9 to 69.4
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Serum
889
10.8
9.2 to 13.1

Urine
559
20.5
17.6 to 24.3

Vaginal
45
9.9
6.6 to 17.9

Figure 4. Estimated percentage of patients with virus detectable by rRT-PCR by
specimen type.
100

A

75
50
25
0
100

B

Proportion of cases with detectable Zika virus RNA (%)

75
50
25
0
100

C

75
50
25
0
100

D

75
50
25
0
100

E

75
50
25
0
100

F

75
50
25
0
100

G

75
50
25
0
25

50

75

Days collected post-symptom onset
A: blood, B: CSF, C: saliva, D: semen, E: serum, F: urine, G: vaginal.
Shaded areas indicate 95% CrI.
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Viral isolation data were available for 119 cases and 417 individual specimens.
Serum was the specimen type most commonly cultured, followed by both semen and
urine (Table 9). Overall, only 38 (13.9%) viral isolation attempts were successful. Semen,
serum, and urine all exhibited similar recovery rates (15.8% to 19.8%). Notably, the
recovery rate of blood and saliva was quite low. Vero (African monkey kidney) cell lines
were utilized most often, followed by C6/36 (Ae. albopictus) cell lines; both had similar
isolation recovery rates (14.9% and 16.7%, respectively). The timing of specimen
collection for isolation attempts ranged from 0 to 201 days post-symptom onset.
Interestingly, there was no significant difference observed in the ability to successfully
culture ZIKV over time; recovery rates are fairly similar through first four weeks
following symptom onset but decreases thereafter.
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Table 9. Viral culture attempts.
Successful
n (%)
58 (13.9)

Unsuccessful Total
n (%)
n (%)
359 (86.1)
417 (100.0)

Total
Specimen type
Blood
0 (0.0)
33 (100.0)
33 (7.9)
CSF
0 (0.0)
2 (100.0)
2 (0.5)
Saliva
3 (5.4)
53 (94.6)
56 (13.4)
Semen
18 (19.8)
73 (80.2)
91 (21.8)
Serum
19 (15.8)
101 (84.2)
120 (28.8)
Urine
16 (17.6)
75 (82.4)
91 (21.8)
Other
2 (8.3)
22 (91.7)
24 (5.8)
Cell line
BALB/c
3 (10.3)
26 (89.7)
29 (7.0)
C6/36
17 (16.7)
85 (83.3)
102 (24.5)
LLC-MK2
0 (0.0)
17 (100.0)
17 (4.1)
Vero*
35 (14.9)
200 (85.1)
235 (56.4)
Unknown
1 (3.2)
30 (96.8)
31 (7.4)
Other
2 (66.7)
1 (33.3)
3 (0.7)
DCPSO†
≤7
23 (16.3)
118 (83.7)
141 (33.8)
8-14
7 (20.6)
27 (79.4)
34 (8.2)
15-21
6 (15.8)
32 (84.2)
38 (9.1)
22-28
4 (19.0)
17 (81.0)
21 (5.0)
≥29
7 (6.7)
97 (93.3)
104 (24.9)
Unknown
11 (13.9)
68 (86.1)
79 (18.9)
*Vero lines included Vero, Vero-E6, and Vero-B4
† Days collected post symptom onset

p-value
0.033

0.017

0.221

Discussion
The incubation period of ZIKV infection in symptomatic patients was estimated
to be 6.5 days. This is very similar to the estimate of 5.9 days by Lessler and colleagues
(9). This estimate is also similar to a study published in 2017 that found the median
incubation period to be 5.8 days (10) and another that calculated the median incubation
period to be 6.8 days (11).
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In the Lessler study, the time to viral clearance in serum specimens was found to
be 9.9 days. The current study found the time to viral clearance in serum to be 10.8 days.
The current study adapted Lessler’s methods and increased the sample size through
conducting an updated systematic review following the ZIKV pandemic. It should also be
noted that Lessler’s analysis evaluated viral clearance from infection as opposed to date
of symptom onset, as in the current study. These results differ slightly with viral
clearance estimates calculated in a prospective cohort followed for six months (12). In
that cohort, serum had a median time to viral clearance of 15 days, and the median
clearance time in urine specimens was 11 days. This is nearly half as long as the estimate
of 20.5 days derived from this systematic review. The estimates for median viral
clearance in semen, however, were similar (42 days in the prospective cohort versus 47.7
days in this study). The present study’s results for blood, serum, and urine also closely
matched those of another prospective cohort conducted after this systematic review (13).
In that cohort study, whole blood specimens were observed to be positive in 89% of
specimens collected through 79 days post-symptom onset. Urine positivity dropped from
75% in specimens collected between 12 and 19 DCPSO to 14% in those collected
between 20 and 36 DCPSO. Although all specimens in that cohort were collected starting
at day six post-symptom onset, none of the 116 serum specimens were positive,
indicating rapid viral clearance from serum.
The availability and quality of viral isolation data varied significantly amongst
records making analysis challenging. The substantial variability of isolation
methodologies, from chosen cell line to number of passages and detection methods,
makes comparability of results difficult as these can have a significant effect on recovery.
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Most notably, the virus was unable to be isolated from any blood specimens and only
5.4% of saliva specimens. The lack of success in isolating the virus from blood is
interesting given the extended detection of viral RNA in blood specimens. As all 33
attempts using blood were cultured with Vero or C6/36 cells, the difficulty in isolating
the virus from blood does not appear to be related to cell line. This could indicate that
molecular methods are only detecting remnants of the virus as opposed to viable RNA.
There could also be a potential inhibitor in whole blood that makes viral isolation
difficult.
Some of the difference between viral clearance estimates may be due to
differences in analytical methodologies. These differences may also be due to limitations
in utilizing data derived from a systematic review of the literature. Although this
systematic review builds upon the earlier work conducted by Lessler and colleagues, the
data presented across the wide variety of records reviewed was highly variable in its
presentation and quality. For example, data were only available in 11.7% of the 792 cases
to be able to determine the incubation period, potentially indicating a bias that could
influence the resulting estimate. Similarly, availability of rRT-PCR results was often
unavailable, likely due to lack of routine serial testing, potentially limiting the accuracy
of viral clearance estimates. These inconsistencies indicate a need for a uniform method
for reporting pertinent and complete data for case reports and case series of infectious
with infectious diseases. Sample size was also limited for certain specimen types,
especially CSF and vaginal specimens. The uneven distribution of specimen types also
reflects the use of serum in serological testing and, potentially, the paradigm that serum is
the specimen of choice for diagnosing ZIKV infection. This study is also limited by the
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variability in diagnostic testing methodologies; the varying sensitivities of rRT-PCR
assays could potentially impact their ability to detect viral RNA, especially as viral load
decreases. These estimates can only be applied to symptomatic cases of ZIKV disease as
asymptomatic cases were not included. Lastly, these viral clearance estimates must be
interpreted cautiously, as they were measured using rRT-PCR methods and do not
necessarily reflect viability of the virus to infect other cells. This is helpful for
establishing diagnostic criteria, but not necessarily in determining if a patient is still
infectious.
Understanding the natural history of infections with ZIKV is critical to controlling
its spread in communities. Knowing the virus’ incubation period allows clinicians and
public health practitioners to better assess potential exposure to the virus. Insight into the
rate of viral clearance in various specimen types also aids in the correct application and
interpretation of test results. Testing algorithms, especially for molecular assays, should
take into account the variability observed in different specimen type to maximize
detection of infections with ZIKV. This is especially important given the poor ability of
current serological assays to discriminate between different Flaviviridae infections. The
different rate of viral clearance between serum and blood specimens may also have
implications for the donation of different blood components.
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Chapter 4
Characterization of Viral Load
Background
The worldwide outbreak of ZIKV disease beginning in 2015 was challenging for
both clinicians and public health agencies because the nonspecific and often absent
symptoms associated with the virus made detecting infections particularly difficult. Up to
80% of infections are thought to be asymptomatic (1, 2), and even when symptoms
present, they are not pathognomonic and usually mild in nature (3). This makes the initial
detection of the disease difficult and potentially allows the virus to establish itself in a
community prior to detection (4-6). Further compounding the issue is the low viral load
observed in routine clinical specimens, such as serum and urine (7-11). Serological
methods, including the detection of IgM against ZIKV or PRNT for ZIKV, are also
complicated by the cross-reactivity of the virus with other flaviviruses, especially DENV
(1, 12). This makes diagnosis by serological methods challenging and, often, results in an
inconclusive or unconfirmed diagnosis (12, 13). Given the emergence of ZIKV as a
public health threat, diagnostic assays that can fully overcome these obstacles have not
yet been developed (14). Understanding the viral load in easily obtainable clinical
specimens can help optimize the development and utilization of such assays.
Viral load can be quantitated using rRT-PCR assays. These assays directly detect
the genetic material of the pathogen in the patient’s specimen. For true quantitation of
viral load with these tests, an internal control or standard must be added to the specimen
and amplified alongside the pathogen’s DNA or RNA. Viral load testing has become a
standard of practice for monitoring the progression of and providing treatment for both
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human immunodeficiency virus and hepatitis C virus. When an internal standard is not
used, the rRT-PCR test is generally referred to as a semi-quantitative assay. The resulting
cycle threshold (Ct) value is an indication of the amount of virus in the specimen. Ct
values have recently been used to monitor the progression of Ebola virus disease in
patients and predict patient outcomes (15-18) . Semi-quantitative rRT-PCR has also been
used in the recent outbreak of the severe acute respiratory syndrome coronavirus 2 in
China to monitor the progression of the virus (19) .
The dramatic increase in the number of cases of Zika virus disease seen since
2015 has given researchers an opportunity to learn more about this once rare virus and
the disease it causes. As part of its routine surveillance activities, the Florida DOH
investigates reports of potential cases of ZIKV infection in Florida. From 2016 to 2017,
the Florida DOH identified 1,733 cases of ZIKV infection (20), including those that were
travel-associated and those that were locally acquired. As part of these investigations,
epidemiological data were gathered and diagnostic specimens tested, providing valuable,
high fidelity data that can provide insight into the course of the disease. Herein, we utilize
these data to estimate the progression of viremia and the time to viral clearance in in
whole blood, serum, and urine specimens.
Methods
Confirmed and probable cases of non-congenital ZIKV infection identified from
2016 to 2017 through testing performed at one of the three locations of the Florida
DOH’s Bureau of Public Health Laboratories (BPHL), were included in this study.
Although the case definition for ZIKV infection changed over the course of the response,
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the case definition typically included some variation of clinically compatible disease,
complication of pregnancy, or neurologic symptoms, and laboratory evidence supporting
the diagnosis of ZIKV infections (21). Confirmed cases were those meeting general
epidemiological criteria with either unambiguous serological results (positive IgM
ELISA, positive neutralizing antibody titers against ZIKV, and negative neutralizing
antibodies against DENV) or RNA detected by rRT-PCR. Probable cases were those
meeting epidemiological criteria with no positive rRT-PCR result and ambiguous
serological results (22). In this analysis, both travel-associated and locally acquired cases
were included. Asymptomatic and congenitally acquired cases were excluded as no
symptom onset date could be determined. This study was reviewed and approved by both
the Florida DOH and Florida International University (FIU) Institutional Review Boards.
Clinical and epidemiological data were obtained from Merlin, the Florida DOH’s
surveillance database. The data utilized in this study included gender, age, pregnancy
status, YFV vaccination status, case status (confirmed or probable), and symptoms,
including fever, rash, headache, joint pain, conjunctivitis, and muscle pain. Clinical and
epidemiological data were typically self-reported to investigators. Corresponding
laboratory results were obtained from the BPHL’s laboratory information system (LIS)
and assay run reports. Laboratory variables included specimen type; days collected postsymptom onset (DCPSO, calculated by subtracting the date of symptom onset from the
date of specimen collection); type of rRT-PCR assay; and Ct value. Both sets of data
were linked by matching Merlin and LIS identifiers and then de-identified for analysis.
Specimens were tested according to the testing algorithm in place at the time of
collection. Molecular detection of ZIKV was accomplished through one of two rRT-PCR
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assays, a laboratory-developed test (LDT) previously described (7) and the CDC’s
Trioplex rRT-PCR Assay (23). The former was primarily used at two of the BPHL
locations during 2016 before transitioning to the Trioplex Assay in 2017; the third BPHL
location used the Trioplex Assay exclusively. Although three primer and probe sets for
three separate RNA targets were utilized with the LDT, only one target was utilized when
comparing Ct values as it matched the target of the Trioplex Assay. Further, the LDT was
always performed in duplicate; whereas the Trioplex Assay was performed in singlicate.
When two Ct values were reported, the mean of the two values was utilized for this study;
if only one of the replicates demonstrated amplification, the single value was used. In
practice, each rRT-PCR assay has an established cutoff value and is typically reported as
detected, not detected, or equivocal. In this study, however, Ct values were analyzed
without regard to these cutoff values as this represents amplification of the viral target.
Descriptive analysis of the study population and laboratory results was conducted.
Dataset characteristics were compared using the Chi-square Test or Fisher’s Exact Test,
where appropriate, using a significance level of 0.05. A logistic regression model was
created to predict the detection of ZIKV RNA by rRT-PCR (any specimen with a Ct
value without regard to the cutoff value), the dependent variable, and identify factors
associated with the clearance of viral RNA. The independent variables included specimen
type, DCPSO, age, gender, and number of key symptoms. Pregnancy status was assessed
through a second logistic model that only included females. Independent variables with
an adjusted odds ratio (aOR) 95% confidence interval (95% CI) including 1.00 were
excluded from the final model. In order to account for repeated measures due to repeated
sampling (multiple specimens collected on multiple days post-symptom onset) on some,
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but not all, cases, PROC GENMOD with the logit link function and Bonferonni
correction for multiple comparisons were utilized for this analysis. Statistical analyses
were performed using software using SAS software version 9.4 (Cary, NC, USA).
Results
A total of 2,044 specimens tested by rRT-PCR, representing 934 cases, were
included in this study. ZIKV RNA was detected in 75.7% (707) of these cases (Table 1).
ZIKV RNA was detected in at least one urine specimen in 61.6% (575) of cases, in at
least one serum specimen in 44.4% (415) of cases, and in at least one whole blood
specimen in 3.3% (31) of cases (data not shown). As expected, given the importance of
rRT-PCR in the case definition ZIKV, the majority of included cases (824, 88.2%) were
confirmed as ZIKV infections (Table 1). Of the 934 cases, 535 (57.3%) were identified in
females. The mean ages of females and males were 40.1 and 41.3 years, respectively. Of
the 535 women included in this study, 32 (6.0%) were pregnant at the time of detection
(Table 1). The most commonly reported symptom was rash (93.6%; 874). Of cases, 74
(7.0%) reported being vaccinated against YFV, and 282 (30.2%) were unaware of their
vaccination status. The median DCPSO for females was 5 days versus 4 days for males.
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Table 1. Demographic and clinical characteristics of patients with confirmed and
probable ZIKV infection.

Total
Case status
Confirmed
Probable
RNA detected in at least
one specimen
Yes
No
Specimen detection†
Serum
Urine
Whole blood
Pregnancy status
Pregnant
Not pregnant
Age (years)
Mean
Range
0-4
5-9
10-19
20-29
30-39
40-49
50-59
≥60
Symptoms‡
Rash
Fever
Arthralgia
Conjunctivitis
Myalgia
Headache
Number of key
symptoms
Zero
One
Two
Three
Four

Female
n (%)
535 (57.3)

Male
n (%)
399 (42.7)

Total
n (%)
934 (100.0)

461 (86.2)
74 (13.8)

363 (91.0)
36 (9.0)

824 (88.2)
110 (11.8)

394 (73.6)
141 (26.4)

313 (78.4)
86 (21.6)

707 (75.7)
227 (24.3)

p-value*
0.024

0.091
0.312
232 (41.1)
320 (56.6)
13 (2.3)

183 (40.1)
255 (55.9)
18 (3.9)

415 (58.7)
575 (81.3)
31 (4.4)

32 (6.0)
503 (94.0)

-

32 (6.0)
503 (94.0)
0.266

40.1
1-81
3 (0.6)
7 (1.3)
32 (6.0)
107 (20.0)
131 (24.5)
101 (18.9)
88 (16.5)
66 (12.3)

41.3
1-86
1 (0.3)
5 (1.3)
31 (7.8)
56 (14.0)
94 (23.6)
84 (21.1)
81 (20.3)
47 (11.8)

40.6
1-86
4 (0.4)
12 (1.3)
63 (6.8)
163 (17.5)
225 (24.1)
185 (19.8)
169 (18.1)
113 (12.1)

509 (95.1)
342 (63.9)
345 (64.5)
234 (43.7)
167 (31.2)
163 (30.5)

365 (91.5)
309 (77.4)
252 (63.2)
163 (40.9)
134 (33.6)
124 (31.1)

874 (93.6)
651 (69.7)
597 (63.9)
397 (32.2)
301 (32.2)
287 (30.7)

0.024
<0.001
0.676
0.377
0.444
0.842
0.098

1 (0.2)
30 (5.61)
91 (17.0)
202 (37.7)
130 (24.3)

0 (0.0)
16 (4.0)
79 (19.8)
120 (30.1)
117 (29.3)
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1 (0.1)
46 (4.9)
170 (18.2)
322 (34.5)
247 (26.5)

Five
Six
YFV§ vaccination ever
Vaccinated
Not vaccinated
Unknown

64 (12.0)
17 (3.2)

57 (14.3)
10 (2.5)

121 (13.0)
27 (2.9)
0.035

38 (7.1)
350 (65.4)
147 (27.5)

36 (9.0)
228 (57.1)
135 (33.8)

74 (7.9)
578 (61.9)
282 (30.2)

Days collected postsymptom onset
<0.001
Total specimens
1,208 (59.1)
836 (40.9) 2,044 (100.0)
Range
-4 to 300
-4 to 267
-4 to 300
Mean
20.1
10.2
16.1
Median
5
4
5
<0
2 (0.2)
6 (0.7)
8 (0.4)
0-3
425 (35.2)
325 (38.9) 750 (36.7)
4-7
307 (25.4)
252 (30.1) 559 (27.4)
8-11
95 (7.9)
63 (7.5)
158 (7.7)
12-15
57 (4.7)
51 (6.1)
108 (5.3)
16-19
41 (3.4)
25 (3.0)
66 (3.2)
20-23
37 (3.1)
29 (3.5)
66 (3.2)
24-27
37 (3.1)
18 (2.2)
55 (2.7)
≥28
207 (17.1)
67 (8.0)
274 (13.4)
*Chi-square test for all comparisons except number of key symptoms and days collected
post-symptom onset (Fisher’s Exact Test); significance level of 0.05.
†by rRT-PCR
‡ Cases may have more than one symptom; percentages will not add up to 100
§Yellow fever virus

Of the 2,044 collected specimens, 1,208 (59.1%) were collected from females
(Table 2). Serum was the specimen collected most frequently (1,052; 51.5%), followed
by urine (904; 44.2%) and whole blood (88; 4.3%) (Table 2). Specimens were collected
between -4 and 300 days with almost two-thirds of specimens (1,317; 64.4%) collected
within a week of symptom onset (Table 1).
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Table 2. rRT-PCR results by specimen type and gender.
Serum
Detected

Female

Male

Total

262 (41.5)

191
(45.5)
229
(54.5)
420
(39.9)

453 (43.1)

Not detected

370 (58.5)

Total

632 (60.1)

Urine
Detected

599 (56.9)
1,052 (100.0)
0.003

333 (62.4)

Not detected

201 (37.6)

Total

534 (59.1)

Whole blood
Detected
Not detected
Total
Total
Detected

p-value*
0.197

266
(71.9)
104
(28.1)
370
(40.1)

599 (66.3)
305 (33.7)
904 (100.0)
0.573

14 (33.3)
28 (66.7)
42 (47.7)

18 (39.1)
28 (60.9)
46 (52.3)

32 (36.4)
56 (63.6)
88 (100.0)
0.004

609 (50.4)

475
1,084 (53.0)
(56.8)
Not detected
599 (49.6)
361
960 (47.0)
(43.2)
Total
1,208 (59.1) 836
2,044 (100.0)
(40.9)
*p-values determined conducting univariate regression between gender and detection
outcome stratifying by specimen type
ZIKV RNA was detected in 53.0% of all specimens (Table 3) with ZIKV RNA
being detected most often in urine specimens (66.3%), followed by serum (43.1%), and
whole blood (36.4%). ZIKV RNA was detected in 71.9% of male urine specimens as
compared to 62.4% of female urine specimens (p = 0.003) (Table 2). Of those cases
where both serum and urine were collected on the same day (n = 708), ZIKV RNA was
detected in both serum and urine in 277 (39.1%) cases; in only urine in 257 (36.3%)
cases; in only serum in 47 (6.6%) cases and not detected in either specimen type in 127
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(17.9%) cases (Table 4). For each DCPSO group except <0, ZIKV was detected in urine
at a higher frequency than in serum.
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Table 3. ZIKV RNA detected by specimen type and days collected post-symptom onset.
Days collected
post-symptom
onset
<0
0-3
4-7
8-11
12-15
16-19
20-23
24-27
≥28
Total

Serum
Tested
4
395
302
76
47
30
30
26
142
1,052

Detected
3
247
126
28
7
6
6
1
29
453

%
75.0
62.5
41.7
36.8
14.9
20.0
20.0
3.8
20.4
43.1

Urine
Tested
3
349
249
71
45
30
31
22
104
904

Detected
0
280
221
42
22
11
9
4
10
599

%
0.0
80.2
88.8
59.2
48.9
36.7
29.0
18.2
9.6
66.3
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Whole blood
Tested Detected
1
1
6
3
8
3
11
3
16
7
6
1
5
2
7
2
28
10
88
32

%
100.0
50.0
37.5
27.3
43.8
16.7
40.0
28.6
35.7
36.4

Total
Tested
8
750
559
158
108
66
66
55
274
2,044

Detected
4
530
350
73
36
18
17
7
49
1,084

%
50.0
70.7
62.6
46.2
33.3
27.3
25.8
12.7
17.9
53.0

Table 4. Comparison of ZIKV RNA detection amongst 708 paired serum and urine specimens collected on the same day postsymptom onset.
Day
collected
post
symptom
onset
<0
0-3
4-7
8-11
12-15
16-19
20-23
24-27
≥28
Total

Pairs
tested n
2
303
231
45
27
17
16
10
57
708

Serum
detected
n (%)
2 (100.0)
186 (61.4)
100 (43.3)
13 (28.9)
5 (18.5)
3 (17.6)
5 (31.3)
0 (0.0)
2 (3.5)
314 (44.4)

Serum only
detected
n (%)
2 (100.0)
27 (8.9)
7 (3.0)
2 (4.4)
1 (3.7)
1 (5.9)
1 (6.3)
0 (0.0)
6 (10.5)
47 (6.6)

Urine detected
n (%)
0 (0.0)
265 (87.5)
205 (88.7)
32 (71.1)
13 (48.1)
5 (29.4)
6 (37.5)
1 (10.0)
7 (12.3)
534 (75.4)
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Urine only
detected
n (%)
0 (0.0)
106 (35.0)
112 (48.5)
21 (46.7)
9 (33.3)
3 (17.6)
2 (12.5)
1 (10.0)
3 (5.3)
257 (36.3)

Neither
detected
n (%)
0 (0.0)
11 (3.6)
19 (8.2)
11 (24.4)
13 (48.1)
11 (64.7)
9 (56.3)
9 (90.0)
44 (77.2)
127 (17.9)

Both
detected
n (%)
0 (0.0)
159 (52.5)
93 (40.3)
11 (24.4)
4 (14.8)
2 (11.8)
4 (25.0)
0 (0.0)
4 (7.0)
277 (39.1)

Almost half (48.9%) of all positive specimens were collected within three days of
symptom onset (Table 3). Among specimens collected at 4 weeks or greater, 49 (17.9%)
had detectable ZIKV RNA. At the extreme, ZIKV RNA was detected in a serum
specimen at 127 DCPSO, urine at 64 DCPSO, and whole blood at 94 DCPSO. The
detection of ZIKV RNA within serum appears to peak before or near the onset of
symptoms and declines thereafter; whereas the detection of ZIKV RNA within urine
appears to peak near the end of the first week after symptom onset and then steadily
declines. Although the sample size is much smaller, the detection of ZIKV RNA within
whole blood appears to remain relatively steady over most of the DCPSO groups (Figure
1). Of the positive whole blood specimens, 10 (31.3%) were collected ≥28 days postsymptom onset. Boxplots of Ct values by each DCPSO group also indicate the decreasing
trend of viral load over time (Figure 2).
Figure 1. Proportion of specimens with ZIKV RNA detected* over time.

*Detection is defined as any amplification above the threshold
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Figure 2. Boxplot of Ct values* by days collected post-symptom onset group

*Ct values are inversely proportional to viral load.
DCPSO: days collected post-symptom onset
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Of the 1,084 specimens with detectable ZIKV RNA, 1,082 had Ct values
available, allowing viral load to be assessed by proxy. Visualization and normality testing
of Ct values indicated that the distribution of Ct values is not normal (Figure 3),
necessitating the use of non-parametric tests. The median Ct values of serum, urine, and
whole blood were 35.3 (IQR = 3.8), 32.9 (IQR = 5.0), and 35.6 (IQR = 2.6), respectively
(Table 5). The highest and lowest Ct values observed were 15.9 and 40.0, respectively,
both in serum. Notably, the lowest Ct value observed in whole blood was 27.5, collected
the day before symptom onset. The range of urine Ct values appears to be similar to that
of serum.

Figure 3. Distribution of Ct values from A) all 1,082 specimens with detectable ZIKV
RNA, B) serum specimens only, C) urine specimens only, and D) whole blood specimens
only.

A

C

B

D
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Table 5. Comparison of median Ct values of specimens with detectable RNA.

Total
Gender
Female
Male
Age group
≤ 18 years
>18 years
Specimen type
Serum
Urine
Whole blood
Pregnancy status
Pregnant
Not pregnant
YFV* vaccination status
Vaccinated
Not vaccinated
Unknown
Symptoms
Rash present
Rash absent
Fever present
Fever absent
Arthralgia present
Arthralgia absent
Conjunctivitis present
Conjunctivitis absent
Myalgia present
Myalgia absent
Headache present
Headache absent
Number of key symptoms
One
Two
Three
Four
Five
Six
*Yellow Fever Virus

n

Median
Ct value

Interquartile
Range
Range

608
474

34.2
34.0

5.2
4.9

20.5 to 38.6
15.9 to 40.0

74
1,008

34.5
34.1

3.8
5.2

26.2 to 39.0
15.9 to 40.0

453
597
32

35.3
32.9
35.6

3.8
5.0
2.6

15.9 to 40.0
18.9 to 39.7
27.5 to 38.4

72
536

35.2
33.9

3.8
5.3

27.4 to 38.6
20.5 to 38.6

93
668
321

34.2
34.2
33.8

4.7
5.1
5.4

22.4 to 38.2
20.5 to 39.7
15.9 to 40.0

1,037
45
782
300
675
407
486
596
364
718
341
741

34.1
34.2
34.2
34.0
33.9
34.4
33.9
34.3
34.1
34.1
33.9
34.2

5.1
6.3
5.2
4.9
5.3
4.9
5.3
4.9
5.2
5.1
5.0
5.2

15.9 to 40.0
21.2 to 37.8
15.9 to 39.7
25.2 to 40.0
20.5 to 39.7
15.9 to 40.0
18.9 to 40.0
15.9 to 39.7
18.9 to 39.7
15.9 to 39.7
20.5 to 39.7
15.9 to 40.0

35
185
381
293
151
35

34.5
33.7
34.5
34.0
33.5
33.7

4.5
5.4
4.6
5.3
5.8
5.2

25.4 to 37.4
15.9 to 40.0
24.5 to 38.6
18.9 to 39.1
21.1 to 39.7
20.5 to 38.1
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There does not appear to be a difference in median Ct value between specimens
collected from females and males or between specimens collected from those 18 years
old or younger and those older than 18 (Table 5). Median Ct values of the specimens
from pregnant (n = 72) and non-pregnant (n = 536) women appear to be lower among
nonpregnant women (35.2 versus 33.9). This appears to be due to the extended sampling
conducted on pregnant women. When only specimens collected within three weeks were
compared, there was no significant difference (p = 0.704). Conversely, the median Ct
values of specimens from those that were previously vaccinated against YFV (n = 93),
those that were not vaccinated (n = 668), and those with an unknown vaccination status
(n = 321) did not appear to be different. Median Ct values by symptom presentation all
appear to be fairly similar, showing no more than 0.5 Ct difference amongst any of the
groups. Similarly, no differences were observed based on the total number of symptoms
reported.
The logistic regression model confirmed the significance of specimen type on the
detection of ZIKV RNA (Table 6). The final model included specimen type (whole
blood, serum, and urine), DCPSO, age, and an interaction effect between specimen type
and DCPSO. The adjusted odds of detection in urine was significantly greater than in
whole blood (aOR = 8.04, 95% CI 4.34 to 14.87). The adjusted odds of detection was
slightly greater in serum than in whole blood (OR = 1.51, 95% CI 0.84 to 2.72), but was
not statistically significant. Age, gender, and key symptoms were found to be
insignificant and not included in the final model (data not shown). Within the females
only model, pregnancy was also found to be a significant indicator for the detection of
ZIKV RNA (aOR = 3.29, 95% CI 1.89 to 5.74). To assess for a bias caused by extended
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sampling of pregnant women with respect to DCPSO, the analysis was limited to
specimens collected at three weeks or less (as noted above), and similar results were
observed (aOR = 3.33, 95% CI 1.62 to 6.81; data not shown). DCPSO and the interaction
effect between DCPSO and specimen types were included in the final model as the Type
3 analysis of effects showed significance. The interaction between urine and DCPSO was
significant (aOR = 0.91, 95% CI 0.88 to 0.94), indicating that the odds of detection in
urine decrease as DCPSO increases. To confirm the effect of DCPSO on specimen type,
logistic regression was conducted to predict detection using DCPSO alone on each
individual specimen type. Urine (OR = 0.90, 95% CI 0.88 to 0.93) and serum (OR = 0.97,
95% CI 0.95 to 0.99) were found to be significant but whole blood (OR = 0.99, 95% CI
0.98 to 1.00) was not. In other words, the rate of viral clearance in urine and serum
appear to occur more rapidly than in whole blood.
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Table 6. Adjusted odds ratios for the final logistic regression model (including specimen
type, DCPSO, pregnancy status†, and the interaction between DCPSO and specimen
type) for the detection of ZIKV RNA by rRT-PCR.
Variable

aOR

95% Confidence
Interval

Specimen type
Whole blood
Referent
Referent
Serum
1.51
0.84 to 2.72
Urine
8.04
4.34 to 14.97
DCPSO†
0.99
0.98 to 1.00
Age
1.01
1.00 to 1.02
Pregnant‡
3.29
1.89 to 5.74
Interaction with DCPSO
Whole blood
Referent
Referent
Serum
0.98
0.96 to 1.00
Urine
0.91
0.88 to 0.94
*Bonferroni-adjusted alpha level = 0.017
†Days collected post-symptom onset
‡Pregnancy determined from females-only model

p-value*
<0.001
Referent
0.165
< 0.001
0.220
0.029
< 0.001
0.001
Referent
0.075
< 0.001

Discussion
Detection of viral RNA is the ideal method to conclusively identify acute
infection with ZIKV. Specimen selection and timing of collection is critical to maximize
success in detecting ZIKV RNA. In our dataset, ZIKV RNA was most frequently
detected in urine specimens (66.3%). ZIKV RNA was detected in urine at the highest
frequency of all three specimen types through 19 days post-symptom onset, allowing for
the detection of infection well after the onset of symptoms. ZIKV RNA was detected in
serum in almost two-thirds of specimens collected within 3 days of symptom onset, but
the frequency of detection decreased rapidly thereafter. This is comparable to what has
been reported in New York State (10, 24). However, ZIKV RNA was detected at a lower
rate in serum alone than in New York (6.6% versus 26.2%). In fact, within paired
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specimens, ZIKV RNA was detected in urine alone at nearly six times the frequency as
serum alone in our dataset. This difference may be due in part to expanded testing of
pregnant women, leading to a wider specimen collection window, and the utilization of
systematic surveys, resulting in a potential bias towards urine specimens as
corresponding sera were not collected.
The timing of specimen collection is also critical to maximize the likelihood of
detection of ZIKV. Within the first 4 weeks post-symptom onset, the frequency of
detection of ZIKV RNA in serum was always lower than that of urine. By the beginning
of the second week post-symptom onset, the frequency of detection within serum
specimens decreased by almost half. ZIKV RNA was detected most frequently in urine
specimens. Overall, however, it appears that ZIKV RNA may remain detectable in whole
blood longer over time. Almost a third of positive whole blood specimens were collected
≥28 days post-symptom onset. These observations concur with previous studies (25-27)
and highlight the importance of specimen selection to maximize the detection of ZIKV
RNA in relation to the timing of specimen collection.
Urine specimens demonstrated the highest viral load overall, as indicated by
median Ct value. This coincides with the increased detection of ZIKV RNA in urine
specimens as compared to other specimen types. In a previous study, the viral loads of
urine specimens were observed to be a log higher than those of serum specimens (10) but
were observed to be lower in a separate pediatric cohort (28). A study by Judice and
colleagues (29) compared viral loads between urine and whole blood specimens, finding
that the viral load in urine was higher than that of whole blood specimens. No correlation
was seen between any of the six key symptoms and the viral load of specimens,

74

corresponding with a report from Musso and colleagues (11). These estimates, as in our
study, were determined using rRT-PCR methods and may not truly reflect intact virus.
These findings are important when considering appropriate testing strategies for
ZIKV. Current guidance for rRT-PCR requires paired specimens when testing any
specimen type other than serum, meaning serum must always be collected at the same
time as urine or other specimens, if they are to be tested. Although this is due in part to
the importance of serological diagnosis of ZIKV, it also contributes to a paradigm that
serum is the single most important specimen type for rRT-PCR and potentially prohibits
testing when serum is not collected along with urine, whole blood, or other specimen
types. In fact, all 11 rRT-PCR assays currently approved for emergency use in the United
States and able to test specimens other than serum or plasma require matched specimens
(30). The experiences of the FDOH also challenge the testing algorithms currently
recommended by the CDC. These guidelines suggest that rRT-PCR testing should be
limited to specimens collected within 7 days of symptom onset(31). As demonstrated in
this study, ZIKV RNA can be detected in approximately a quarter of all specimens
collected in the first three or so weeks following symptom onset. Although low, this
could potentially provide unambiguous evidence for ZIKV that may be missed due to
limitations of serological testing. This, of course, must be balanced with the number of
negative results that may be encountered as a result of a wider specimen collection
window.
This study is limited to symptomatic infections with ZIKV. Therefore, it is
impossible to assess complete performance of the assay or the implications of widening
the specimen collection window. Symptom onset date was self-reported, and due to the
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generally mild nature of ZIKV infection, it is possible that patients could not accurately
recall the onset date, which would affect the accuracy of the DCPSO calculation as well
as viral load estimates and characterization of ZIKV detection frequency. However,
patient were was systematically collected by trained interviewers. The small number of
whole blood specimens tested (only 4.3% of all specimens in this dataset) limits the
ability to draw conclusions on the detection and viral load of those specimens. Viral load
was estimated using Ct values produced by rRT-PCR testing and detects viral RNA, not
intact virus. These values serve as a proxy for viral load as they were not quantified using
a true standard curve and internal control and are therefore prone to variation. This
variation can come from operator training and error, degradation in reagents, pipetting
error, and other sources. Further studies should assess viral load through standardized
quantitative rRT-PCR or other accepted methods. Any method relying on rRT-PCR is
limited in that it does not necessarily indicate if the detected virus is viable or not since it
only detects viral RNA.
With the finite amount of laboratory resources to test these specimens, optimizing
specimen collection and testing algorithms is necessary. Understanding the progression
of virus and viral load in various specimen types is critical to refining testing strategies
for ZIKV. Effective utilization of rRT-PCR can assist in limiting the number of
specimens requiring IgM or PRNT for confirmation, both of which require increased time
and resources, are not as readily available as rRT-PCR, and often do not provide
confirmation as intended. Increased reliance on rRT-PCR should allow providers,
patients, and investigators to receive results quicker and potentially provide for fewer
unambiguous results.
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Chapter 5
Evaluation of Testing Guidelines
Background
In the summer of 2016, the Florida DOH detected the first cases of mosquitoborne, locally transmitted ZIKV infections in the continental United States in MiamiDade and Broward Counties (1, 2). This discovery prompted the mobilization of public
health and mosquito control resources in an effort to rapidly contain the outbreak and
protect the health of the state’s residents and visitors (3). As part of this response, the
Florida DOH’s Bureau of Epidemiology (BOE) and BPHL, along with county health
departments, were responsible for investigating suspected cases and testing specimens.
Because of the nonspecific, often absent, symptoms of ZIKV infections (4),
laboratory testing plays a critical role in identifying cases of infections caused by ZIKV.
The most commonly available assays for ZIKV are rRT-PCR tests, which detect the
nucleic acid of the virus directly, and IgM ELISA tests, which identify the host’s
antibody response to a recent infection. A third test, the PRNT, is used to measure the
titer of neutralizing antibodies against the virus (5). Because of the clinical similarities
between infections, DENV testing is often ordered along with ZIKV tests. However,
interpretation of serological assay (IgM and PRNT) results can be complicated by the
cross-reactivity with different flaviviruses (5-8). Similarly, the viral load associated with
ZIKV infections has been reported to be substantially lower than that associated with
other flaviviruses (6, 9) and has been observed to be lower in serum than urine (10). Both
of these factors impact how and when these assays should be used to maximize the
probability of detection while limiting the opportunity for discrepant or unreliable results.
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The CDC provides extensive guidance for testing patients for ZIKV (11) and
updated these guidelines in 2019 to incorporate testing for DENV (12). The intent of this
guidance is to maximize the likelihood of detecting cases while ensuring resources are
not needlessly expended. This is further complicated by the high proportion of
asymptomatic cases and the risk presented to the fetuses of pregnant women (13, 14).
Three separate algorithms are recommended by the CDC for individuals with possible
exposure: non-pregnant symptomatic individuals, pregnant symptomatic women, and
pregnant asymptomatic women. Exposures can include living in or traveling to an area
with risk of ZIKV or unprotected sexual contact with someone at risk of exposure. These
algorithms have been refined as more is learned about the course of infection. Two
significant updates included in the 2019 algorithms include narrowing the specimen
collection window for rRT-PCR to ≤7 days and including testing for IgM against DENV.
The latter significantly increases the number of potential results given by the algorithm.
The 2019 update also includes testing specimens by DENV rRT-PCR, but this is not
addressed here.
Testing during the ZIKV outbreak in Florida was primarily provided by
commercial laboratories, BPHL, and the CDC (15). Positive specimens from commercial
laboratories were referred to BPHL for confirmation. The BPHL is composed of three
public health laboratories located in Jacksonville, Miami, and Tampa. The CDC initially
performed all PRNT testing and provided surge capacity for rRT-PCR and ZIKV IgM
testing during periods of increased volume. The Florida DOH generally relies on the
CDC’s guidance, but also significantly expanded the availability of free testing to
pregnant women following the identification of autochthonous transmission within the
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state (3). Testing conducted by BPHL was also generally expanded to include serological
testing for DENV (both IgM and IgG) due to the large population of foreign-born
residents that may have been exposed to other arboviruses, such as DENV in their
country of birth or during travel. Although testing for DENV IgM is suggested in the
2019 CDC ZIKV testing guidance, this was not generally recommended during the
outbreak. According to the 2016 American Community Survey, an estimated 19.9% of
Florida’s population was born outside of the United States (16). In Miami-Dade County,
where local transmission of ZIKV occurred, approximately 52.2% of the population was
foreign-born. This additional testing for DENV provides critical data on the effectiveness
of the serological assays and allows for retrospective testing of the 2019 updated
guidance.
Understanding how these assays perform is also important when investigating
potential cases of the disease and determining whether cases were acquired locally, as a
result of travel to an endemic area, or acquired through sexual contact. In addition to
these concerns, all three assay types have different demands in terms of complexity, cost,
availability, and turnaround time, requiring laboratories and epidemiologists to optimize
testing algorithms. Using the assay results and epidemiological data from the Florida
DOH, we retrospectively compare the efficacy of the CDC’s 2017 and 2019 testing
strategies for ZIKV in the context of locally acquired and travel-associated cases of the
virus from 2016 and 2017. With the shortening of the specimen collection period, we
expect that laboratory testing is able to confirm significantly fewer infections.
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Methods
Dataset. Cases were identified through both active and passive surveillance
previously described (1, 3, 17). All confirmed and probable cases of ZIKV infection
identified between 2016 and 2017 by the Florida DOH were included in this study except
those acquired congenitally. Generally, confirmed cases are those meeting general
epidemiological criteria, such as residing in or having recent travel to an area with known
ZIKV transmission, and confirmatory laboratory evidence, such as direct detection of
viral RNA or both a positive PRNT (titer ≥ 10) against ZIKV and a negative PRNT (titer
<10) against DENV. Generally, probable cases are those meeting epidemiological criteria
with presumptive laboratory evidence, such as a positive ZIKV IgM result with an
ambiguous PRNT result (18). Both symptomatic and asymptomatic cases were included.
Qualitative molecular and serological laboratory results included in this analysis were
performed by either the BPHL or the CDC; no results from commercial laboratories are
included as they were repeated at the BPHL. Ten specimens were excluded as they were
collected before symptom onset; two specimens collected greater than a year postsymptom onset were excluded. Clinical and epidemiological data were collected through
epidemiological investigations, chart review, and laboratory requisitions. All data were
collected as part of routine public health investigations and were stored in the Florida
DOH’s disease surveillance system. Data on country of birth were not collected and,
therefore, not included in the analysis. Laboratory data were matched to case data by
matching case and specimen identifiers to collection dates. Where discordant results for a
single specimen and collection dates were reported (e.g., if a specimen test was repeated),
the more conclusive result was included. For example, if both an indeterminate and
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positive result were available for the same specimen, the positive result was used in the
analysis as the assay would have been repeated to resolve the indeterminate result. For
algorithm evaluation, equivocal, indeterminate, and inconclusive results were treated as
negative results as these specimens would be further tested in an actual investigation.
Both case-level determinations (e.g., acute infection with ZIKV or infection with
flavivirus) and individual laboratory results are presented. In the context of algorithm
evaluation, cases are adjudicated by meeting particular testing criteria outlined by the
appropriate testing algorithm. Cases were de-duplicated according to hierarchical value
of the algorithm result. Broadly, this hierarchy was prioritized from acute infections,
infections of undetermined timing, presumptive infections, no evidence of infection, and
those with no algorithm result. Protocol approval was granted by both the Florida DOH
and FIU Institutional Review Boards.
Analysis. Descriptive analysis of the dataset was conducted with SAS 9.4. Caseand specimen-level data were used to compare the 2017 and 2019 CDC testing
recommendations (11, 12). Specimens were first categorized according to symptom
presentation (symptomatic or asymptomatic) and pregnancy status to determine with
which CDC algorithm (non-pregnant symptomatic, pregnant symptomatic, or pregnant
asymptomatic) the specimen should be evaluated. Once classified to an algorithm,
specimens were then evaluated per the algorithm based on specimen type and the days
collected post-symptom onset (see Figures 1 through 6). Key differences in algorithms
include decreasing the collection window for rRT-PCR for direct detection of the virus,
incorporating serological analyses for DENV to aid in discriminating infection type and
timing, and expanding algorithm results to include presumptive infections (where PRNT
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results are unavailable). Differences between the performance of the algorithms was
assessed using the test of marginal homogeneity with a significance level of 0.05.
Results
A total of 1,522 cases, encompassing 3,321 individual specimens and 6,841 test
results, were identified and included in this study. As expected, due to the focus of
surveillance on pregnant women, most cases, 1,016 (66.8%), were identified in women
(Table 1). Similarly, most identified cases (72.1%) were symptomatic. Of the 1,016
female cases with identified ZIKV, 37 (3.6%) were pregnant at the time of infection. The
average age of symptomatic and asymptomatic patients was 40.7 and 31.1 years,
respectively. Of note, no asymptomatic cases were identified in children aged 0 to 9.
Most cases (n=1,201; 78.8%) indicated travel to at least one dengue-endemic country.
Table 1. Summary of case characteristics of cases with ZIKV infections in Florida, 20162017.

Gender
Female
Male
Total
Diagnosis status
Confirmed
Probable
Pregnancy status
Pregnant
Not pregnant
Not applicable (male)
Age (years)
Mean
Range
0-4

Symptomatic

Asymptomatic Unknown Total

627 (57.1)
471 (42.9)
1,098 (72.1)

379 (92.2)
32 (7.8)
411 (27.0)

10 (76.9)
3 (23.1)
13 (0.9)

1,016 (66.8)
506 (33.3)
1,522 (100.0)

964 (87.8)
134 (12.2)

56 (13.6)
355 (86.4)

4 (30.8)
9 (69.2)

1,024 (67.3)
498 (32.7)

32 (2.9)
595 (54.2)
471 (42.9)

5 (1.2)
374 (91.0)
32 (7.8)

0 (0.0)
10 (76.9)
3 (23.1)

37 (2.4)
979 (64.3)
506 (33.3)

40.7
1-86
4 (0.4)

31.1
15-89
0 (0.0)

32.4
18-59
0 (0.0)

38.1
1-89
4 (0.3)
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5-9
10-19
20-29
30-39
40-49
50-59
≥60
Travel to dengueendemic countries*
Endemic country
Sporadic or uncertain
Florida only†
Sexually acquired‡
Unknown

14 (1.3)
74 (6.7)
185 (16.9)
265 (24.1)
220 (20.0)
202 (18.4)
134 (12.2)

0 (0.0)
25 (6.1)
163 (39.7)
183 (44.5)
24 (5.8)
7 (1.7)
9 (2.2)

0 (0.0)
1 (7.7)
3 (23.1)
8 (61.5)
0 (0.0)
1 (7.7)
0 (0.0)

14 (0.9)
100 (6.6)
351 (23.1)
456 (30.0)
244 (16.0)
210 (13.8)
143 (9.4)

845 (77.0)
19 (1.7)
228 (20.8)
6 (0.6)
0 (0.0)

349 (84.9)
7 (1.7)
51 (12.4)
0 (0.0)
4 (1.0)

7 (53.9)
0 (0.0)
6 (46.2)
0 (0.0)
0 (0.0)

1,201 (78.9)
26 (1.7)
285 (18.7)
6 (0.4)
4 (0.3)

*CDC Yellow Book 2020 (19) used for determining DENV endemicity.
†Florida only cases had no recent travel.
‡Sexually acquired cases had no recent history of travel or known exposure to local
transmission area, or had laboratory evidence of supporting sexual transmission.
Of the 3,321 specimens, 2,926 (88.1%) were tested by rRT-PCR for ZIKV; 1,423
(42.8%) by ZIKV IgM; 1,071 (32.2%) by DENV IgM; 699 (21.0%) by ZIKV PRNT; and
722 (21.7%) by DENV PRNT (Table 2). The most commonly tested specimen type was
serum (1,954; 58.8%), followed by urine (1,259; 37.9%) and whole blood (108; 3.3%).
Of those specimens tested by rRT-PCR, 45.3% (1,326) were reported as detected,
indicating presence of the virus. ZIKV was detected most frequently in urine specimens
(729 out of 1,259; 57.9%), followed by serum (568 out of 1,559; 36.4%) and whole blood
(29 out 108; 26.9%). Notably, only 4.1% (24) of asymptomatic cases tested positive for
ZIKV by rRT-PCR as compared to 56.1% (1,300) of symptomatic cases. Conversely,
72.6% (365) of asymptomatic cases were positive for ZIKV IgM as compared to 67.6%
(612) of symptomatic cases. Of the 1,112 sera that were tested by both ZIKV rRT-PCR
and IgM, only 10.7% (119) were positive in both tests.
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Table 2. Summary of laboratory results for 3,321 specimens from 1,522 cases with ZIKV
infections in Florida, 2016-2017.
ZIKV RT-PCR, n
(%)
Detected
Equivocal
Not detected
Total
ZIKV IgM, n (%)
Positive
Equivocal
Negative
Inconclusive
Indeterminate
Total
DENV IgM, n
(%)
Positive
Equivocal
Negative
Inconclusive
Indeterminate
Total
ZIKV PRNT, n
(%)
Positive
Negative
Total
DENV PRNT, n
(%)
Positive
Negative
Total

Symptomatic

Asymptomatic Unknown

Total

1,300 (56.1)
78 (3.4)
941 (40.6)
2,319 (79.3)

24 (4.1)
2 (0.3)
567 (95.6)
593 (20.3)

2 (14.3)
0 (0.0)
12 (85.7)
14 (0.5)

1,326 (45.3)
80 (2.7)
1,520 (2.0)
2,926(100.0)

612 (67.6)
38 (4.2)
245 (27.0)
1 (0.1)
10 (1.1)
906 (63.7)

365 (72.6)
74 (14.7)
39 (7.8)
1 (0.2)
24 (4.8)
503 (35.4)

11 (78.6)
1 (7.1)
2 (14.3)
0 (0.0)
0 (0.0)
14 (1.0)

988 (69.4)
113 (7.9)
286 (20.1)
2 (0.1)
34 (2.4)
1,423 (100.0)

109 (15.1)
9 (1.2)
604 (83.5)
0 (0.0)
1 (0.1)
723 (67.5)

32 (9.4)
5 (1.5)
300 (88.2)
2 (0.6)
1 (0.3)
340 (31.8)

2 (25.0)
0 (0.0)
6 (75.0)
0 (0.0)
0 (0.0)
8 (0.8)

143 (13.4)
14 (1.3)
910 (85.0)
2 (0.2)
2 (0.2)
1,071 (100.0)

261 (98.5)
4 (1.5)
265 (37.9)

423 (99.8)
1 (0.2)
424 (60.7)

10 (100.0)
0 (0.0)
10 (1.4)

694 (99.3)
5 (0.7)
699 (100.0)

155 (56.4)
120 (43.6)
275 (38.1)

395 (90.6)
41 (9.4)
436 (60.4)

9 (81.8)
2 (18.2)
11 (1.5)

559 (77.4)
163 (22.6)
722 (100.0)

1,423 specimens (72.8% of serum specimens collected) were tested for IgM
against ZIKV; 988 (69.4%) were positive. 1,071 specimens (54.7% of serum specimens
collected) were tested for IgM against DENV. DENV IgM was positive in 13.4% (143)
of these specimens. Of those specimens that were tested by both DENV IgM and ZIKV
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IgM (n=982), 12.9% (127) of those that tested positive for IgM against ZIKV also tested
positive for DENV IgM. In specimens that tested positive by rRT-PCR for ZIKV and
were tested for IgM against DENV, 9.0% (19) were positive for both.
Six hundred ninety-nine and 722 sera were tested for ZIKV and DENV by PRNT,
respectively. Of these, 99.3% (694) were positive for ZIKV, and 77.4% (559) were
positive for DENV. Both test results were available for 691 sera, and 420 of these
specimens were associated with asymptomatic cases, only 4 of which were from pregnant
cases. Of the 691 sera tested by both ZIKV and DENV PRNT, 531 (76.8%) were positive
for both ZIKV and DENV, 155 (22.4%) were positive for ZIKV alone, and 5 (0.7%)
were negative for both viruses.
Using the CDC 2017 testing guidelines, 1,105 cases would have been eligible for
testing: 1,066 cases would have been tested using the symptomatic non-pregnant
algorithm, 32 cases with the symptomatic pregnant algorithm, and 5 with the
asymptomatic pregnant algorithm. Four hundred nineteen cases were identified by the
Florida DOH that would not have been tested according to these recommendations (Table
3). Figures 1-6 depict the number of specimens and cases in each of the 3 algorithms for
2017 and 3 algorithms for 2019. After accounting for duplicate cases, the 2017 algorithm
identified 820 cases (74.3%) that would have been adjudicated as acute infections with
ZIKV, 75 (6.8%) as infections with ZIKV with undetermined timing, 102 (9.2%) as
flavivirus infections with undetermined timing, 39 (3.5%) as no evidence of ZIKV
infection, 32 (2.9%) with no algorithm result, and 35 (3.2%) that would have been
excluded due to collection timing. The 2019 algorithm identified 761 (69.0%) acute
infections, 140 (12.7%) recent or presumptive ZIKV infections, 112 (10.2%) recent or
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presumptive flavivirus infections, 1 (0.1%) presumptive DENV infection, 19 (1.7%) with
no evidence of ZIKV or DENV infection, 26 (2.4%) with no algorithm result, and 44
(4.0%) that were excluded for testing due to collection timing.
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Table 3. Theoretical comparison of 2017 and 2019 Centers for Disease Control and Prevention Algorithms’ performance---Results
that would have been seen had each of the algorithms been used.

Total specimens in category

2017 Algorithms
NPS* PS
PA
2,288 179
34

Patients represented in category

1,066

32

Specimens collected ≤13 or 7
days post-symptom onset‡

1,817

Specimens collected >13 or 7
days post-symptom onset‡
Specimens tested by ZIKV
NAAT
Positive (%)
Negative or equivocal (%)
Specimens tested by ZIKV and/or
DENV IgM
Non-negative (%)
Negative (%)

Total
2,501

2019 Algorithms
NPS
PS
2,288 179

PA
34

Total
2,501

5

1,103

1,066

32

5

1,103

54

-

1,871

1,581

41

-

1,622

254

125

-

379

256

107

-

363

1,753
1,153
(65.8)
597
(34.1)

171
74
(43.3)
97
(56.7)

30
6
(20.0)
24
(80.0)

1,954
1,233
(63.1)
718
(36.7)

1,531
1,064
(69.5)
467
(30.5)

141
70
(49.7)
71
(50.4)

30
6
(20.0)
24
(80.0)

1,702
1,140
(67.0)
562
(33.0)

591
502
(84.9)
89
(15.1)

95
84
(88.4)
11
(11.6)

-

686
586
(85.4)
100
(14.6)

596
565
(94.8)
31
(5.2)

78
69
(88.5)
9
(11.5)

-

674
634
(94.1)
40
(5.9)

-
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-

Tested by ZIKV and DENV
PRNT
ZIKV ≥10
DENV <10
ZIKV ≥10
DENV ≥10
ZIKV <10
(DENV <10)
Case determination

235
107
(45.5)
126
(53.6)
2
(0.9)

13
4
(30.8)
9
(69.2)
0
(0.0)

-

207
105
(50.7)
99
(47.8)
3
(1.4)

11
3
(27.3)
8
(72.7)
0
(0.0)

-

-

248
111
(44.8)
135
(54.4)
2
(0.8)

-

218
108
(49.5)
107
(49.1)
3
(1.4)

Acute ZIKV infection

783
(73.5)

32
(100.0)

5
(100.0)

820
726
(74.3) (68.1)

30
(93.8)

5
(100.0)

761
(69.0)

Recent or presumptive ZIKV
infection

75
(7.0)

0
(0.0)

0
(0.0)

75
(6.8)

140
(13.1)

0
(0.0)

0
(0.0)

140
(12.7)

Recent or presumptive flavivirus
infection

102
(9.6)

0
(0.0)

0
(0.0)

102
(9.2)

111
(10.4)

1
(3.1)

0
(0.0)

112
(10.2)

Recent or presumptive DENV
infection

0
(0.0)

0
(0.0)

0
(0.0)

0
(0.0)

1
(0.1)

0
(0.0)

0
(0.0)

1
(0.1)

No evidence of ZIKV or DENV
infection

39
(3.7)

0
(0.0)

0
(0.0)

39
(3.5)

19
(1.8)

0
(0.0)

0
(0.0)

19
(1.7)

No algorithm result

32
(3.0)

0
(0.0)

0
(0.0)

32
(2.9)

26
(2.4)

0
(0.0)

0
(0.0)

26
(2.4)

-

-

35
0
0
35
43
1
0
44
Excluded from testing
(3.3)
(0.0)
(0.0)
(3.2) (4.0)
(3.1)
(0.0)
(4.0)
*NPS: non-pregnant symptomatic cases; PS: pregnant symptomatic cases; PA: pregnant asymptomatic cases
† p-value from two sample proportions test (two-tailed) between algorithm totals; results significant at p<0.05.
‡Specimens collected ≤13 and 7 days post-symptom onset for the 2017 and 2019 algorithms, respectively.
91

Figure 1. 2017 CDC recommended testing algorithm for non-pregnant, asymptomatic
cases.

Total Specimens
2,288 specimens 1,066 cases
1,241 sera 964 urine
83 whole blood

Specimen Collected ≥14
Days Post-symptom
Onset

Specimen Collected <14
Days Post-symptom
Onset

471 specimens 207 cases
254 sera 167 urine
50 whole blood

1,817 specimens 921 cases
987 sera 797 urine
33 whole blood

Positive ZIKV NAAT

Non-positive ZIKV NAAT

Not Tested by ZIKV NAAT

Not Tested by NAAT

1,156 specimens 783 cases
494 sera 653 urine
9 whole blood

597 specimens 490 cases
426 sera 147 urine
24 whole blood

68 specimens 66 cases
68 sera

217 specimens 148 cases
167 urine 50 whole blood
35 post-deduplication

Not Tested Further

ZIKV IgM Serology

168 specimens 156 cases
144 urine 24 whole blood

747 sera 629 cases

Non-negative ZIKV IgM

Not Tested by ZIKV IgM

Negative ZIKV IgM

502 sera 452 cases

156 sera 151 cases

89 sera 87 cases

Needs PRNT
658 sera 560 cases

Complete PRNT Results

Incomplete or No PRNT
Results Available

235 sera 223 cases

423 sera 382 cases

Acute ZIKV
Infection
783 cases

ZIKV PRNT ≥10
DENV <10

ZIKV PRNT ≥10
DENV ≥ 10

107 sera 101 cases

126 sera 120 cases

ZIKV Infection,
Undetermined
Timing

Flavivirus Infection,
Undetermined
Timing

101 cases
75 post-deduplication

120 cases
102 post-deduplication
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ZIKV PRNT <10
2 serum 2 cases

No Evidence Of
ZIKV Infection

No Algorithm
Interpretation

235 cases
39 post-deduplication

382 cases
32 post-deduplication

Figure 2. 2017 CDC recommended testing algorithm for pregnant, symptomatic cases.

Symptomatic Pregnant Women With
Possible Exposure
179 specimens 32 cases

Concurrent ZIKV NAAT & IgM Testing
103 sera 70 urine 6 whole blood

Positive ZIKV NAAT
74 specimens 32 cases
48 sera 23 urine
3 whole blood

Non-positive ZIKV NAAT
& Non-negative ZIKV IgM

Non-negative Urine
& WB NAAT

Negative ZIKV NAAT
& Negative ZIKV IgM

Negative Urine & WB
ZIKV NAAT

52 sera 22 cases

1 specimen 1 case
1 urine 0 whole blood

3 sera 3 cases

49 specimens 19 cases
46 urine 3 whole blood

Complete PRNT Results
13 sera 11 cases

Incomplete or No PRNT
Results Available
39 sera 20 cases

Acute ZIKV
Infection
74 specimens
32 cases

ZIKV PRNT ≥10
DENV <10

ZIKV PRNT ≥10
DENV ≥ 10

4 sera 3 cases

9 sera 9 cases

ZIKV Infection,
Undetermined
Timing

Flavivirus
Infection,
Undetermined
Timing

3 cases
0 post-deduplication

ZIKV PRNT <10
0 sera 0 cases

No Evidence Of
ZIKV Infection

No Algorithm
Interpretation

20 cases
0 post-deduplication

20 cases
0 post-deduplication

9 cases
0 post-deduplication
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Figure 3. 2017 CDC recommended testing algorithm for pregnant, asymptomatic cases.

Asymptomatic Pregnant Women With
Possible Exposure
34 specimens 5 cases
20 sera 14 urine

ZIKV NAAT Testing
34 specimens 5 cases
20 sera 14 urine

Positive ZIKV NAAT

Negative ZIKV NAAT

Not Tested by NAAT

6 specimens 5 cases
6 sera 0 urine

24 specimens 4 cases
10 sera 14 urine

4 specimens 3 cases
4 sera

Acute ZIKV Infection

No RNA Detected,
Infection Cannot Be Ruled Out

5 cases

4 cases
0 post-deduplication
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Figure 4. 2019 CDC recommended testing algorithm for non-pregnant, asymptomatic cases.

Specimen Collected ≤7
Days Post-symptom
Onset

Specimen Collected >7
Days to ≤12 Weeks Postsymptom Onset

1,581 specimens 834 cases
866 sera 701 urine
14 whole blood

634 specimens 275 cases
329 sera 239 urine
66 whole blood

Not Tested (not serum)
305 specimens 218 cases
239 urine 66 whole blood

Not Tested (too old)
73 specimens 43 cases
46 sera 24 urine
3 whole blood

Positive ZIKV NAAT

1,064 specimens 726 cases
463 sera 596 urine
5 whole blood

Non-positive ZIKV NAAT
467 specimens 420 cases
353 sera 105 urine
9 whole blood

Not Tested Further

117 specimens 117 cases
108 urine 9 whole blood

50 specimens 49 cases
50 sera

Needs ZIKV & DENV IgM

ZIKV IgM Negative
DENV IgM Negative
31 sera 31 cases

Not Tested by ZIKV NAAT

732 sera 616 cases

Non-negative ZIKV
and/or DENV IgM*
565 sera 507 cases

Not Tested by ZIKV &
DENV IgM
136 sera 131 cases

Incomplete or No PRNT
Results Available

Needs PRNT

701 sera 590 cases

No Algorithm Result^
30 sera 30 cases

494 sera 444 cases

Both IgM Not Tested
Final
109 sera 105 cases

No Algorithm
Result

Complete PRNT Results

134 cases
26 post-deduplication

207 sera 196 cases

ZIKV PRNT <10
DENV PRNT <10

ZIKV PRNT <10
DENV ≥10

ZIKV PRNT ≥10
DENV ≥ 10
99 sera 95 cases

105 sera 98 cases

ZIKV PRNT ≥10
DENV <10

ZIKV IgM Positive
DENV IgM Negative

ZIKV IgM Negative
DENV IgM Positive

No Evidence of
ZIKV or DENV
Infection

Recent DENV
Infection

Recent Flavivirus
Infection

Recent ZIKV
Infection

Presumptive ZIKV
Infection

Presumptive DENV
Infection

3 sera 3 cases

Acute ZIKV
Infection
726 cases

149 cases
10 post-deduplication

0 sera 0 cases

0 cases
0 post-deduplication

95 cases
80 post-deduplication

98 cases
80 post-deduplication

174 sera 171 cases

171 cases
60 post-deduplication

1 serum 1 case

1 case
1 post-deduplication
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ZIKV IgM Positive
DENV IgM Not Tested
46 sera 44 cases

ZIKV IgM Not Tested
DENV IgM Positive
2 sera 2 cases

Presumptive
Flavivirus Infection
91 cases
31 post-deduplication

ZIKV IgM Positive
DENV IgM Positive
46 sera 45 cases

ZIKV IgM Not Tested
DENV IgM Negative

ZIKV IgM Negative
DENV IgM Not Tested

No Evidence of
DENV Infection

No Evidence of
ZIKV Infection

34 sera 34 cases

34 cases
1 post-deduplication

52 sera 51 cases

51 cases
8 post-deduplication

Figure 5. 2019 CDC recommended testing algorithm for pregnant, symptomatic cases.

Symptomatic Pregnant Women With
Possible Exposure
179 specimens 32 cases
103 sera 70 urine
6 whole blood

Not Tested (Too Old)

Concurrent ZIKV NAAT & IgM Testing
Specimens Collected ≤12 Weeks Post-symptom Onset

31 specimens 8 cases
17 sera 13 urine
1 whole blood
1 case post-deduplication

148 specimens 31 cases
86 sera 57 urine 5 whole blood

Positive ZIKV NAAT

Non-positive ZIKV NAAT
&
Non-negative ZIKV or DENV
IgM

70 specimens 30 cases
44 sera 23 urine
3 whole blood

Negative Urine & WB ZIKV
NAAT
35 specimens 16 cases
33 urine 2 whole blood

Negative ZIKV NAAT
&
Negative ZIKV or DENV IgM

Non-negative Urine & WB
ZIKV NAAT
1 specimen 1 cases
1 urine

1 sera 1 cases

41 sera 19 cases

Incomplete or No
PRNT Results
30 sera 17 cases

Complete PRNT
Results

No Algorithm Result

11 sera 9 cases

ZIKV PRNT ≥10
DENV <10

ZIKV PRNT <10
DENV ≥10

ZIKV PRNT ≥10
DENV ≥ 10

ZIKV PRNT <10
DENV PRNT <10

ZIKV IgM Positive
DENV IgM Negative

ZIKV IgM Negative
DENV IgM Positive

ZIKV Infection,
Undetermined
Timing

DENV Infection,
Undetermined
Timing

Flavivirus
Infection,
Undetermined
Timing

No Evidence Of
ZIKV Infection

Presumptive ZIKV
Infection

Presumptive DENV
Infection

3 sera 2 cases

Acute ZIKV
Infection
30 cases

3 sera 2 cases

2 cases
0 post-deduplication

0 sera 0 cases

0 cases
0 post-deduplication

8 sera 8 cases

0 sera 0 cases

1 case
0 post-deduplication

12 sera 10 cases

10 cases
0 post-deduplication

0 serum 0 cases

0 cases
0 post-deduplication

8 cases
1 post-deduplication
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ZIKV IgM Positive
DENV IgM Not Tested
11 sera 8 cases

ZIKV IgM Not Tested
DENV IgM Positive
0 serum 0 cases

Presumptive
Flavivirus Infection
11 cases
0 post-deduplication

ZIKV IgM Positive
DENV IgM Positive
4 sera 3 cases

No Algorithm Result
2 cases
0 post-deduplication

ZIKV IgM Not Tested
DENV IgM Negative

ZIKV IgM Negative
DENV IgM Not Tested

No Evidence of
DENV Infection

No Evidence of
ZIKV Infection

0 serum 0 cases

0 cases
0 post-deduplication

0 serum 0 cases

0 cases
0 post-deduplication

Figure 6. 2019 CDC recommended testing algorithm for pregnant, asymptomatic cases.

Asymptomatic Pregnant Women With
Possible Exposure
34 specimens 5 cases
20 sera 14 urine

ZIKV NAAT Testing

30 specimens 5 cases
16 sera 14 urine

Positive ZIKV NAAT

Negative ZIKV NAAT

Not Tested by PCR

Acute ZIKV Infection

No RNA Detected,
Infection Cannot Be Ruled Out

No Algorithm Result

6 specimens 5 cases
6 sera 0 urine

5 cases

24 specimens 4 cases
10 sera 14 urine

4 cases
0 post-deduplication

4 specimens 3 cases
3 sera

3 cases
0 post-deduplication

When analyzed using the 2017 algorithm, only 44.8% (111) of those specimens
tested against both ZIKV and DENV for PRNT were positive against only ZIKV; 49.5%
(108) of those analyzed with the 2019 algorithm were positive against only ZIKV. 135
(54.4%) and 107 (49.1%) of specimens were positive against both ZIKV and DENV
using the 2017 and 2019 algorithms, respectively. Interestingly, only 30.8% (4) and
27.3% (3) of specimens from pregnant, symptomatic women were positive against only
ZIKV with the 2017 and 2019 algorithms, respectively.
Compared with the 2019 testing algorithm, the 2017 testing algorithm resulted in
definitively identifying 59 more cases as acute infections. In addition to identifying fewer
acute infections, the 2019 testing algorithm identified almost twice as many recent or
presumptive cases of ZIKV infections than the earlier algorithm. Conversely, the 2019
algorithm categorized approximately half as many cases as having no evidence of ZIKV
or DENV infection. Overall, there was a significant difference between the two
algorithms (x2 = 81.2, df = 6, p < 0.001).
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Discussion
Retrospective analysis of the 2017 and 2019 testing algorithms demonstrates the
challenging task of diagnosing ZIKV infections. The CDC strategy relies upon separating
potential cases by presentation of symptoms and further focusing testing efforts on
pregnant women due to the increased risks associated with ZIKV. This strategy focuses
resources on the population most severely affected by ZIKV and attempts to limit falsepositive results that could result in anxiety in pregnant mothers and unnecessary
abortions. However, a major limitation to this approach is that there is no allowance for
testing of non-pregnant, asymptomatic patients. Between 2016 and 2017, the Florida
DOH identified 419 confirmed and probable cases of ZIKV infection in non-pregnant,
asymptomatic patients. This accounted for 27.5% of all cases in the dataset. With both
the 2017 and 2019 testing algorithms, these patients would not have been tested. This
group must be accounted for when investigating potential cases or outbreaks and setting
up surveillance systems as asymptomatic cases are thought to account for approximately
80% of all cases (4) and can serve as a source of infection (20).
Evidence suggests that the viral load observed in patients infected with ZIKV is
generally low (6, 9, 10), limiting the utility of rRT-PCR. The 2019 algorithm limits the
specimen collection window to ≤7 days compared to ≤13 days in the 2017 algorithm. Of
the 1,326 PCR-positive specimens with associated collection dates, 1,097 (82.7%)
specimens were collected ≤7 days. Extending the collection window to ≤13 days
increases the number of positive results to 1,202 (90.6%) specimens. If the collection
window was expanded to ≤28 days, 95.2% (1,262) of the specimens that tested positive
by rRT-PCR would be included in the algorithm. Part of the increase in recent or
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presumptive ZIKV infections observed in the 2019 algorithm as compared to the 2017
algorithm can be attributed to the shortening of the specimen collection window for rRTPCR testing. Of these additional 68 cases, 23.5% (16 cases) would have been adjudicated
as acute cases with a collection window ≤13 days; this increases to 30.9% (21 cases) with
a specimen collection window of ≤28 days. A larger testing window, for ZIKV may be
indicated as detection of viral RNA allows investigators to unequivocally determine the
timing of infection as compared to serological testing. Because ZIKV RNA was detected
in far fewer asymptomatic cases (4.1%), testing of non-pregnant, asymptomatic patients
could potentially be limited to further optimize future algorithms while expanding
specimen collection windows. However, even a small increase in the number of cases
adjudicated by rRT-PCR could potentially save time and resources in performing
extraneous serological testing due to the high specificity of the assay. Further, rRT-PCR
generally has a much quicker turnaround time and is much more readily available in
laboratories as compared to IgM and PRNT testing. Real-time RT-PCR capacity is also
much easier to quickly expand in the event of an outbreak (21, 22).
Of specimens tested for IgM antibodies against both ZIKV and DENV, 12.9%
were positive for both, demonstrating the potential for cross-reactivity. This concurs with
other studies that have assessed the cross-reactivity of the two viruses (7). In a cohort of
61 patients diagnosed with acute ZIKV infection from Brazil, Felix and colleagues
evaluated the cross-reactivity with several DENV IgM assays, finding up to 16.4% and
37.7% cross-reactivity, depending on the assay and date of collection (23). This level of
cross-reactivity and the potential for false-positive results make relying upon ZIKV IgM
assays challenging, especially when patient treatment and other decision-making is
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dictated by the outcome. This is further complicated in locations where DENV is
prevalent or populations with increased prior exposure to DENV.
The performance and resulting utility of the PRNT assay for the determination of
disease etiology is limited. About half of the cases with both ZIKV and DENV PRNT
results were able to distinguish ZIKV as the etiology according to the 2017 and 2019
algorithms, 44.8% and 49.5% respectively. The percentage was even lower in pregnant
cases, although the sample size for this group is relatively small. The inability of the
PRNT assay to identify the specific etiology for such a large percentage of cases may be,
in part, due to the exposure of patients to other flaviviruses, such as DENV, through
travel. The large number of foreign-born residents in Florida, and in Miami-Dade County
in particular, may also influence the performance of this assay (8). With the amount of
effort, time, and resources that goes into performing these tests, the resulting outcome
needs to be considered. Additionally, the PRNT assay is a very specialized test, relying
on time-consuming cell culture methods, and is not readily available in most laboratories.
In Florida, the PRNT assay is only performed in one laboratory in the state, BPHLTampa, creating potential delays in testing due to shipping requirements. As in other
locations, the inclusion of the PRNT assay must be considered within the context of
geography and the outbreak itself (11, 12, 24).
The CDC recently revised its testing guidance for ZIKV given the decreased risk
of transmission world-wide and the prolonged persistence of IgM antibodies to ZIKV
(25, 26). This update only recommends serologic testing in cases consistent with
congenital ZIKV infection and residence or travel to an area at risk of ZIKV; ZIKV IgM
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testing is not recommended for symptomatic or asymptomatic pregnant patients. This will
place more reliance on rRT-PCR testing to identify outbreaks of ZIKV in the future.
These analyses are subject to several limitations. This study utilizes laboratory
and epidemiological data collected during the ZIKV outbreak from 2016 to 2017 to
retrospectively test these algorithms. This approach treats specimens from the same
patient collected on different dates and analyzes them independently. In a practical
setting, multiple laboratory results from multiple specimens would be analyzed together,
along with other available data, to determine the etiology and nature of infection. Deduplicating cases hierarchically attempts to account for this. However, this approach also
clearly demonstrates the variability of results across time and the difficulty of diagnosing
ZIKV infections with currently available laboratory tests. Using only confirmed and
probable cases also limits the utility of this analysis to evaluating the efficacy in terms of
presumably true cases. To comprehensively evaluate testing guidance and assays, the
inclusion of non-case data is also important. This additional data would allow for
evaluation of non-ZIKV infections in the testing algorithms, such as those caused by
DENV.
Epidemiologists and health care providers need to be cognizant of the limitations
of testing for ZIKV. Current guidance for testing is limited in that it potentially does not
account for approximately 80% of cases as testing of asymptomatic patients is limited to
pregnant patients. This guidance focuses on patient diagnosis for those most at risk and
does not account for critical public health surveillance activities. Public health agencies
will need to adapt these recommendations in order to effectively detect and identify
future transmission of ZIKV. In the context of an outbreak, asymptomatic people must be
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included on the basis of epidemiological factors in an attempt to balance disease
detection and laboratory resources. Expansion of the specimen collection window for
rRT-PCR testing, especially in response to an outbreak, can potentially maximize the
availability of laboratory resources by limiting the need for serological testing. This can
also include use of the PRNT assay, which, in some populations, may be of limited
utility.
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Chapter 6
Conclusion and Recommendations
Conclusion
The unprecedented worldwide spread of ZIKV offered a unique opportunity to
study a once rare infection. Because of the significant increase in infections,
complications with fetal development and an increased risk of neurologic complications
were identified as being associated with ZIKV infections. The surge in cases also brought
the development and implementation of new diagnostic assays, providing a wealth of
both clinical and laboratory data. The studies presented herein sought to capitalize on this
increase in evidence to investigate the natural history of the virus.
The first study, a systematic review of published cases, estimated the median
incubation period of ZIKV disease to be 6.5 days from exposure. Abstracted data were
also used to calculate median viral RNA clearance time from symptom onset from
various clinical specimens. Vaginal and serum specimens were observed to have the
quickest time to viral clearance, 9.9 and 10.8 days, respectively; whereas, semen and
whole blood specimens had the longest time to viral clearance, 47.7 and 49.2 days,
respectively. Saliva and urine had similar times to viral clearance, 18.9 and 20.5 days,
respectively. These estimates can be used to adapt testing methodologies and algorithms
to optimize the detection of infections with ZIKV. This can be especially important given
the challenges of identifying acute infections using serological methods, such as IgM or
PRNT.
As an extension of viral clearance time, available viral isolation data were
examined as a proxy for infectivity. Due to both the tremendous variability in viral
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isolation methods and the inconsistency in reporting these methods, it was difficult to
make direct comparisons and analyze these variables in aggregate. Overall, only 13.9%
of viral isolation attempts resulted in recovery of the virus. Semen, serum, and urine all
exhibited similar recovery rates. However, virus was not recovered from whole blood in
any of the 33 attempts, indicating it is a poor specimen choice for viral isolation attempts.
This indicates that, although ZIKV can be detected longest in whole blood specimens by
rRT-PCR, these specimens may not actually be infectious for the entire duration that in
which ZIKV can be detected by rRT-PCR.
The second study built upon this systematic review by utilizing data collected by
the Florida DOH on confirmed and probable symptomatic cases between 2016 and 2017.
Of the 2,044 specimens included in the study, ZIKV was detected most often in urine
specimens, and, when collected alongside serum specimens, were detected in 75.4% of
specimens as compared to 44.4% of serum specimens. Within the first four weeks
following symptom onset, ZIKV RNA was detected at higher rates in urine specimens as
compared to serum specimens. Urine also had the lowest median Ct value, indicating a
significantly higher viral load than whole blood or serum. These findings indicate that
urine may be the ideal specimen for detecting ZIKV RNA by rRT-PCR. However, almost
a third of positive whole blood specimens were detected ³28 days post-symptom onset,
indicating the potential utility of using whole blood to diagnose older infections.
The final study examined case data from the ZIKV outbreak in Florida from 2016
to 2017 in the context of diagnostic algorithms. Epidemiological and laboratory data were
utilized to retrospectively assess the efficacy of the CDC’s recommend algorithms for
diagnosing Zika virus disease. The transition to a shorter recommended collection time
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for molecular testing led to fewer determinations of acute ZIKV infection and a
corresponding increase in the identification of recent or presumptive cases of ZIKV
infection. Both algorithms exclude testing of specimens from asymptomatic people who
are not pregnant. In the experience of Florida, strict application of this recommendation
would have resulted in the potential failure to detect 419 cases.
Within this dataset, 12.9% of specimens tested for IgM antibodies against both
ZIKV and DENV were positive for both. Of the 691 specimens tested by both ZIKV and
DENV PRNT, 531 (76.8%) were positive for both viruses. Nine percent of specimens
that were positive for ZIKV by rRT-PCR and tested for IgM antibodies against DENV
were also positive by DENV IgM. This adds to the body of evidence that serological
methods for flaviviruses are non-specific, causing difficulties in interpreting their results.
Increased reliance on molecular detection and a larger specimen collection window could
potentially alleviate the reliance upon serological methods while still identifying the
majority of cases.

Recommendations
These findings underscore the importance that laboratory testing plays when
responding to public health emergencies. Especially with an infection where a large
proportion of cases are asymptomatic or symptoms are mild or non-pathognomonic,
appropriate utilization and interpretation of laboratory testing is critical. When resources
are limited, these factors become even more important. With regard to ZIKV, these
studies add to the mounting evidence that urine may be the optimal specimen to utilize as
a diagnostic specimen. Given the higher viral load, the ability to detect ZIKV RNA
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within the first three weeks of infection with urine, and the relative ease of specimen
collection, prioritizing urine collection may aid in identifying more acute cases.
Additionally, urine is a relatively simple and non-invasive specimen to collect, making it
ideal for surveillance studies.
Utilization of urine alone, however, may not be the optimum strategy. Given the
lengthened time to viral clearance for whole blood specimens, there is a place for whole
blood in the diagnostic algorithm as well. Whole blood could potentially be used in cases
where infection with ZIKV is highly suspected and other etiologies are ruled out. These
studies suggest that ZIKV RNA could be detected in whole blood for upwards of two
months following symptom onset. If serological testing is inconclusive in such cases,
testing whole blood can be considered.
Further review of the window for specimen collection for routine molecular
testing needs to be reexamined. Current CDC guidelines recommend limiting molecular
testing to specimens collected within 7 days from symptom onset. These studies
demonstrate that ZIKV RNA can be regularly detected in urine specimens for at least two
weeks, if not three. As mentioned previously, further analyses must be conducted to
determine if the additional testing volume would be offset by the ability to identify these
additional cases. Given the challenges with serological testing and widespread ability to
implement molecular testing, it appears this additional testing may be worthwhile.
Lastly, current testing algorithms do not account for asymptomatic cases in nonpregnant individuals. Given that up to 80% of all infections with ZIKV are asymptomatic
and that most infections are mild, consideration for testing asymptomatic patients must be
given. Strategies must be devised to account for this population without overloading the
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laboratory system. Pooling specimens from asymptomatic patients may be an effective
approach that can strike a balance with the volume of testing and the benefit for public
health surveillance.
The unprecedented emergence of ZIKV illuminated many of the deficiencies
within our global health system. The pandemic, however, taught the lesson of flexibility.
With the increased number of cases, came an increase in our knowledge of the virus and
its effects on its host. Leveraging this lesson and newfound knowledge will be critical in
responding and controlling the next outbreak of ZIKV and other emerging illnesses.
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